Association between prolactin and mammographic breast density by Leiras, Claudia Costa
 
 
 
ASSOCIATION BETWEEN PROLACTIN AND  
 
MAMMOGRAPHIC BREAST DENSITY 
 
 
 
 
 
 
 
 
by 
 
Claudia Costa Leiras 
 
BS, College of Mount Saint Vincent, 1997 
 
MS, University at Buffalo, 2000 
 
 
 
 
 
 
 
 
 
Submitted to the Graduate Faculty of 
 
Graduate School of Public Heath in partial fulfillment  
 
of the requirements for the degree of 
 
Doctor of Philosophy 
 
 
 
 
 
 
 
 
University of Pittsburgh 
 
2009 
 ii 
 
 
 
 
 
 
UNIVERSITY OF PITTSBURGH 
 
GRADUATE SCHOOL OF PUBLIC HEALTH 
 
 
 
 
This dissertation was presented 
 
by 
 
 
Claudia Costa Leiras 
 
 
It was defended on 
 
April 7, 2009 
 
and approved by 
 
M. Michael Barmada, PhD, Director, Center for Computational Genetics and Associate 
Professor, Department of Human Genetics, Graduate School of Public Health, 
University of Pittsburgh 
 
Joel L. Weissfeld, MD, MPH, Associate Professor, Department of Epidemiology, Graduate 
School of Public Health and Assistant Professor of Medicine, School of Medicine,  
University of Pittsburgh 
 
John W. Wilson, PhD, Assistant Professor, Department of Biostatistics, Graduate School of 
Public Health, University of Pittsburgh 
 
Anthony J. Zeleznik, PhD, Profesor, Department of Cell Biology and Physiology, School of 
Medicine, University of Pittsburgh 
 
Jane A. Cauley, DrPH, Vice Chair for Research and Professor, Department of 
Epidemiology, Graduate School of Public Health and Associate Professor,  
School of Nursing, University of Pittsburgh 
Dissertation Advisor 
 iii 
 
Copyright © by Claudia Costa Leiras 
 
2009 
Jane A. Cauley, DrPH 
 
iv 
 
ASSOCIATION BETWEEN PROLACTIN AND  
 
MAMMOGRAPHIC BREAST DENSITY 
 
Claudia Costa Leiras, PhD 
 
University of Pittsburgh, 2009 
 
 
Breast density affects mammographic sensitivity and is predictive of breast cancer risk.  Factors 
that increase breast density may compromise the reduction in mortality gained by 
mammographic screening.  Understanding these factors is crucial as it may help us improve 
mammographic screening and reduce breast cancer risk. Prolactin, an endogenous hormone that 
acts as a mitogen and differentiating agent in the breast, may be one such factor. To our 
knowledge, this is the first study to examine the association between prolactin and 
mammographic breast density in a cross-sectional study of healthy, cancer-free postmenopausal 
women. 
 A weak, but statistically significant correlation was observed between prolactin and 
percent breast density (spearman correlation coefficient of 0.1197; p-value 0.013) after adjusting 
for every being pregnant and ever breast feeding.  Prolactin is most likely one of several factors 
that contribute to increased mammographic breast density, and further analyses are needed to 
determine its’ full contribution.  No statistically significant associations were observed for the 
prolactin gene single nucleotide polymorphisms (SNPs) examined in relation to prolactin, 
percent breast density, or proportion of dense breast area. However, two SNPs in the prolactin 
receptor gene (rs7734558 and rs7705216) were significantly associated with serum prolactin 
level at the 0.10 significance level.  Women with the G allele (AG and GG) at SNP rs7734558 
have a slightly elevated level of prolactin when compared with women homozygous for the A 
allele (AG 10.76 ± 6.40 ng/mL, GG 10.77 ± 4.60 ng/mL vs. AA 9.86 ± 6.32 ng/mL); and those 
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v 
 
with the GG allele at SNP rs7705216 have a slightly elevated prolactin level when compared 
with individuals with the C allele (GG 11.71 ± 2.78 ng/mL vs. CG 11.15 ± 6.22 ng/mL, CC 
10.27 ± 5.99 ng/mL). These SNPs need to be further investigated to determine their full 
contribution in relation to serum prolactin levels. 
Having an understanding of factors that affect breast density is an important public health 
issue has it may lead to improvements in breast cancer screening and help identify not only 
women at an increased risk for breast cancer, but women who may benefit from prevention 
strategies. 
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1.0 Introduction 
 
1.1 Breast Cancer Epidemiology 
 
Among women, breast cancer is the most common cancer and is second only to lung cancer in 
the number of deaths per year. In 2006, approximately 212,920 new cases of invasive and 61,980 
cases of in situ breast cancer will be diagnosed in the United States, accounting for 31% of all 
female cancers.1 Approximately, 40,970 women will die from breast cancer, accounting for 
approximately 15% of cancer mortality in women.1  During the past twenty years, while the 
annual breast cancer incident rate has been steadily increasing, the mortality rate has declined by 
approximately 2.3% per year.2 This discrepancy between incident and mortality rates in most 
likely due to cancer screening improvements, leading to the early detection of breast cancer, as 
well as more effective treatment regimens. Data from the National Cancer Institute’s 
Surveillance Epidemiology and End Results (SEER) program show that breast cancer mortality 
rate has declined 2.3% each year between 1990 and 2003.2 The percentage of women surviving 
at least five years after diagnosis has risen to 88% and the 5-year survival is 98% among women 
diagnosed with early stage, localized disease.2 
 
1.1.1 Age and Breast Cancer Risk 
 
With the exception of gender, age is the most scientifically proven breast cancer risk factor. 
Breast cancer seldom occurs in women under the age of 25 years.3 The overall incidence rate for 
women ages 20-24 years is 1.4 per 100,000 women. However, after the age of 25 years, the 
incidence rate rises linearly until the age of menopause, at which point the rates begin to 
plateau.3  Data from SEER indicate that between 1999 and 2003, the incidence rate for breast 
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cancer was 119.3 per 100,000 for women ages 40-44; 249.0 per 100,000 for women ages 50-54; 
and 388.3 for women ages 60-64. The highest rate of breast cancer (490.4 per 100,000) was 
observed in women aged 75-79.3 More than 80% of breast cancer cases occur in women over the 
age of 50 years.4 
 
1.1.2 Race/Ethnicity and Breast Cancer Risk 
 
Breast cancer rates vary by race and/or ethnicity. African-American women have a lower overall 
incidence of breast cancer when compared to Caucasian women (118.9 per 100,000 versus 137.6 
per 100,000, respectively, for 1999-2003, SEER Data),3 but have a higher incidence of breast 
cancer before 35 years of age.2 In addition, African-American women have an overall higher rate 
of breast cancer mortality at all ages than Caucasian women (34.4 deaths per 100,000 versus 25.4 
deaths per 100,000, respectively, for 1999-2003, SEER Data).3 These breast cancer disparities 
are difficult to explain, but several theories have been put forth in an attempt to explain them, 
including: differential utilization of mammographic screening and stage at diagnosis; differential 
effect and/or distribution of breast cancer risk factors; differences in inherent genetic 
susceptibility; differences in tumor characteristics; differential access to treatment; and 
differences in the prevalence of co-morbidities.5 All of these proposed factors have been 
examined, and it appears that the most likely factor responsible for the observed disparities is the 
differential distribution of risk factors, most notably obesity.6 Tumor characteristics7,8 and 
differences in co-morbid conditions9 also appear to contribute, and most likely genetic 
susceptibility10,11 will also play a role (not well understood at this time). As can be seen from the 
lack of evidence, still much research is needed to fully explain the breast cancer disparities 
between African-Americans and Caucasians.  
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Figure 1: Age-specific breast cancer incidence rates among U.S. women by race, 1999-2003. 
 
Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) 
SEER*Stat Database: Incidence-SEER 9 Regs Public-Use, Nov 2005 Sub (1973-2003), National 
Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released 
April 2006, based on the November 2005 submission.3 
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As noted above, between 1999-2003, SEER reported female breast cancer incidence rates 
for Caucasians as 137.6 per 100,000 and for African Americans as 118.9 per 100,000.3 These 
rates are much higher than those reported for other racial groups. Among Asians and Pacific 
Islanders, the breast cancer incidence rate was (per 100,000) 93.5; 87.1 for Hispanics; and 74.4 
for Native Americans and Alaskan Natives.3 Mortality rates during the same period were also 
lower than for both Caucasians and African-Americans (25.4 deaths per 100,000 versus 34.4 
deaths per 100,000, respectively). The mortality rates (per 100,000) for Asians and Pacific 
Islanders was 12.6;  16.3 for Hispanics; and 13.8 for Native Americans and Alaskan Natives.3 
These differences may be attributed to varying genetic, environmental, and behavioral factors. 
Interestingly, age-adjusted breast cancer incidence rates also vary greatly around the 
world. There exists more than a 3-fold difference between high- and low-risk countries.12 High-
risk countries are those considered to be industrialized, like North American and Western 
Europe. The low-risk countries are those considered to be developing nations, most commonly 
found in Asian and Africa. As women migrate from low-risk countries to high-risk countries, 
their breast cancer risk increases. For example, Asian women who live in the East have one of 
the lowest breast cancer rates of any population in the world. When Asian women migrate to 
North America, however, they acquire breast cancer incidence rates similar to the women in the 
host country.13,14 These trends may be partially explained by acculturation and adoption of a 
Western diet.15  
 
1.1.3 Family History and Breast Cancer Risk 
 
Aside from increasing age and geographical region, family history of breast cancer is one of the 
strongest breast cancer risk factors. Women who have a first-degree relative with a history of 
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breast cancer are themselves at an increased risk (OR 1.80, 95% CI 1.69-1.91) as are women 
with two first-degree relatives with a history of breast cancer (OR 2.93, 95% CI 2.36-3.64) when 
compared with women without an affective relative.16 This risk is further increased if the breast 
cancer in the relative is diagnosed at an early age. A woman with a first-degree relative with a 
history of breast cancer diagnosed before the age of 40 years has a 5.7 times greater risk (95% CI 
2.7-11.8) of being diagnosed with breast cancer herself before she is 40 years of age compared to 
a woman of the same age without a family history of breast cancer. 16 
 The BRCA1 and BRCA2 genes have been implicated in familial breast cancer, which 
accounts for less than 10% of all breast cancers.17 These mutations are more strongly related to 
premenopausal breast cancer, which occurs at a younger age. Among women diagnosed with 
breast cancer before 40 years of age, 9% have a BRCA mutation compared to 2% of women of 
any age diagnosed with breast cancer.18 For BRCA1 mutations, the lifetime risk is 50-73% of 
developing breast cancer by the age of 50 years and 65-87% by 70 years of age, and for BRCA2 
mutations, the risk is 59% by the age of 50 years and 82% by 70 years of age. 18 
 
1.1.4 Breast Cancer Risk Factors 
 
How cancer of the breast arises is still not completely understood, but is most likely due to a 
combination of reproductive, hormonal, environmental and genetic factors. The difficulty in fully 
understanding the etiology of breast cancer is partly due to the long duration of sub-clinical 
disease as well as the heterogeneity of the cancer once it is diagnosed. Compounding these issues 
is the observation that risk factors may differ between pre- and post-menopausal breast cancer. 
However, epidemiological studies have been able to identify both risk factors as well as 
protective factors for breast cancer development (Table 1; reviewed by Dumitrescu et al.19). 
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These factors can be classified into two categories – modifiable factors (example: diet and 
physical activity) and non-modifiable factors (example: family history of breast cancer). 
Research has yet to identify a major risk factors that if modified can be used for primary breast 
cancer prevention. 
 
Table 1:  Summary of Breast Cancer Risk Factors.  
Factors that increase breast cancer risk: 
Well-confirmed factors: Magnitude of risk: 
Increasing age ++ 
Geographical region (USA and Western countries) ++ 
Family history of breast cancer ++ 
Mutations in BRCA1 and BRCA2 genes ++ 
Mutations in other high-penetrance genes (p53, ATM, NBS1, LKB1) ++ 
Ionizing radiation exposure (in childhood) ++ 
History of benign breast disease ++ 
Late age at menopause (>54) ++ 
Early age at menarche (<12) ++ 
Nulliparity and older age at first birth ++ 
High mammographic breast density ++ 
Hormone replacement therapy + 
Obesity in postmenopausal women + 
Tall stature + 
Alcohol consumption (~1 drink/day) + 
Probable factors:  
High insulin-like growth factor I (IGF-I) levels ++ 
High prolactin levels + 
High saturated fat and well-done meat intake + 
Polymorphisms in low-penetrance genes + 
High socioeconomic status + 
Factors that decrease breast cancer risk: 
Well-confirmed factors:  
Geographical region (Asia and Africa) -- 
Early age at first full-term pregnancy -- 
Higher parity -- 
Breast feeding (longer duration) -- 
Obesity in premenopausal women - 
Fruit and vegetable consumption - 
Physical activity - 
Probable factors:  
Non-steroidal anti-inflammatory drugs (NSAIDs) - 
Polymorphisms in low-penetrance genes - 
  
 
++ (moderate to high increase in risk) -- (moderate to high decrease in risk) 
+ (low to moderate increase in risk)  - (low to moderate decrease in risk) 
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Reproductive factors have long been implicated in the etiology of breast cancer. Research 
has shown that early age at menarche (<12 years), late age at menopause (>54 years), late age at 
first full-term birth are breast cancer risk factors. Women who started menstruating at 12 years of 
age or younger have a 30% greater risk of developing breast cancer when compared with women 
who started menstruating on or after the age of 15.20 Women who become menopausal at ≥55 
years have a 71% greater risk (95% CI 1.37-2.12) of breast cancer than women who go through 
menopause at <40 years of age.21 Additionally, women who had a first-full term pregnancy after 
the age of 31 years also have an increased breast cancer risk when compared to women whose 
first full-term pregnancy occurred before 18 years of age (RR 1.65, 95% CI 1.40-1.93).22  For 
every five year increase in age for first full-term birth, there is a 20% greater risk (95% CI 1.16-
1.24) for breast cancer development. 22 
 
1.1.5 Estrogens and Breast Cancer Risk  
 
Based on the association between hormonally related risk factors (early age at menarche, late age 
at menopause, and late age at first full-term pregnancy) with increased breast cancer risk, 
differences in endogenous estrogen levels have been theorized to affect breast cancer risk.23-26 
Epidemiological studies have consistently shown that prolonged exposure to high levels of 
estrogen that occur in the menstrual cycle are related to an increased risk of breast cancer among 
postmenopausal women.23-26 In a pooled analysis of nine prospective studies of endogenous 
hormone concentrations and breast cancer risk, serum estradiol concentrations predicted the risk 
of postmenopausal breast cancer. The relative risk for women with the highest quintile of free 
estradiol concentration was 2.58 (95% CI 1.76-3.78) relative to women in the lowest quintile.26 
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In postmenopausal women, body mass index (BMI) is a critical determinant of estrogen 
production. BMI is calculated as weight in kilograms divided by height in meters squared. The 
World Health Organization classifies BMI into four categories: underweight (<18.5 kg/m2), 
normal weight (18.5-24.9 kg/m2), overweight (25.0-29.9 kg/m2), and obsese (≥30.0 kg/m2).27  
Results from the Women’s Health Initiative (WHI) Observational Study confirmed the effect of 
increasing BMI on breast cancer risk among postmenopausal women who have never taken HT. 
Heavier women (baseline BMI >31.1) had an increased risk of postmenopausal breast cancer 
(RR 2.52, 95% CI 1.62-3.93) compared with slimmer women (baseline BMI <22.6).28 Also, 
bone mineral density (BMD), which is considered a surrogate measure of lifetime estrogen 
exposure, is positively associated with breast cancer risk.29   
Extensive data also link the use of HT after menopause, a major source of exogenous 
estrogen exposure in postmenopausal women, to the risk of developing breast cancer. Estimates 
vary, but it is estimated that breast cancer risk increases 10-80% depending on duration of use.30-
32 Results from the WHI indicate that this increased risk may occur among users of combined 
estrogen and progestin formulations30,32, but not among users of unopposed estrogen33,34. Women 
randomized to take a combination formulation had a 24% increased risk of developing invasive 
breast cancer when compared to those randomized to placebo (HR 1.24, 95% CI 1.01-1.54).30 In 
a separate arm of the WHI, women randomized to an unopposed pill had a risk of invasive breast 
cancer similar to those randomized to placebo (HR 0.80, 95% CI 0.62-1.04).34 
When there is an abrupt arrest of estrogen by the ovaries, such as in surgical menopause, 
the risk of breast cancer decreases. In the Multiple Outcomes of Raloxifene Evaluation (MORE) 
trial, women in the highest tertile of estradiol levels had a 2.1 fold increased breast cancer risk 
when compared to women in the lowest tertile of estradiol.35 Women with circulating levels of 
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estradiol >10pmol/L in the Raloxifene group had a breast cancer rate 76% lower (95% CI 53%-
88%) than women with similar levels of estradiol in the placebo group.36 Thus, inhibiting the 
action of estrogen reduces the risk of breast cancer. 
Taken together, these studies all suggest that increased lifetime endogenous and 
exogenous estrogen exposure appears to increase breast cancer risk. Despite the evidence 
implicating estrogens in breast cancer, the underlying mechanism by which estrogens exert their 
effects remains unclear.  
 
1.2 Mammographic Breast Density 
 
Mammography represents the most accepted method for the early detection of breast cancer. A 
radiologist examining a mammogram is able to detect a tumor(s) or other breast abnormalities 
that may lead to breast cancer. Excluding high-risk women with a strong family history of breast 
cancer, the American Cancer Society currently recommends that women over the age of 40 years 
receive annual mammograms to screen for early breast cancer.1 This recommendation is based 
on the observation that the earlier the cancer is detected, the greater the chances for survival. 
Although a mammogram is able to detect tumors (breast cancer), research has indicated that it is 
in fact the composition of the breast that may provide information on breast cancer risk itself.  
The histological composition of the breast is composed of different types of tissue which 
are reflected mammographically by density and parenchymal patterns.37 The dark areas on a 
mammogram represent fatty breast tissue. Because fatty tissue is radiolucent, it allows the x-ray 
beams to pass through it resulting in a dark appearance.  The light areas on a mammogram 
represent fibroglandular tissue, which is composed of stroma, ductal, and glandular tissue. 
Because it is more dense than fatty tissue, the fibroglandular tissue absorbs the x-rays, thus 
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resulting in a light appearance.37 The higher the fat content of the breast, the lower the radiologic 
density. Conversely, a high proportion of stroma or ductal and glandular tissue increases 
density.38,39 Thus,  mammographic breast density is an estimate of the proportion of dense tissues 
in the breast as opposed to fatty tissue.  At menopause, glandular and ductal tissue decreases and 
fibrous connective tissue is usually replaced by fat, explaining the decrease in breast density that 
occurs with age.40-46  
Research suggests that breast tissue aging rather than chronological age has the greatest 
influence on breast cancer risk.47 The theory of breast tissue aging relates to the aging of breast 
tissue – most rapid at menarche, slows with each pregnancy, slows further in the peri-
menopausal period, and is the lowest after menopause. This pattern of breast tissue aging 
corresponds to the pattern observed for breast density. A higher density is observed for pre-
menopausal women, a lower density for women during the peri-menopausal period, and the 
lowest density observed for postmenopausal women.47 
 
1.2.1 Methods of Measuring Breast Density 
 
Since there is no standardized method to assess breast density, a variety of methods, both 
qualitative and quantitative have been developed.  
 
1.2.1.1 Qualitative Breast Density Measurements 
 
Dr. John Wolfe, in 1976, described the first method to associate breast parenchymal patterns and 
breast cancer risk 48.  Breasts were classified by one of four parenchymal patterns – “Wolfe’s 
patterns”:  
1. N1 – primarily fat tissue; no duct pattern is visible; low risk 
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2. P1 – mostly fat tissue but with some dense areas (ductal prominence) of less than 25% of 
the total breast; intermediate risk 
3. P2 – more than 25% of the breast composed of dense tissue along with a noticeable 
ductal pattern; intermediate risk 
4. DY – primarily homogeneous dense tissue and no conspicuous ductal pattern; 
radiographically dense; highest risk  
 
Several studies have used Wolfe’s classification to measure breast cancer risk associated with 
breast density.42,49-54 In three cohort studies,52-54 the DY pattern was associated with an increased 
risk of breast cancer when compared to the N1 pattern.  In both case-control and cohort studies, 
breast density  determined by  Wolfe’s method has been associated with increased breast cancer 
risk (ORs ranging from 1.4-6.2).42,49-54  
Another qualitative method is the Tabar classification.55 This classification is based on the  
anatomic-mammographic correlation and utilizes a three-dimensional, sub-gross (thick-slice) 
technique to describe 5 patterns of breast density: 
1. Pattern I – scalloped contours with some areas of fatty replacement; 1mm evenly 
distributed nodular densities (typical appearance of the premenopausal breast); low risk  
2. Pattern II – complete fatty replacement of tissue; 1 mm evenly distributed nodular 
densities; low risk 
3. Pattern III – prominent ductal pattern in the retroareolar area; low risk 
4. Pattern IV – extensive nodular and linear densities throughout the breast, with nodular 
size larger than normal lobules; high risk 
5. Pattern V – homogenous, extensive fibrosis with an appearance similar to ground glass; 
high risk 
 
Gram et al. reported a poor agreement between the Tabar classification and Wolfe’s patterns 
when comparing high-risk versus low-risk mammograms.55 This mostly liked was because a 
large proportion (45.6%) of the evaluated mammograms were classified as Wolfe pattern DY 
(high risk), but as Tabar Pattern I (low risk).55 This discrepancy may be due to assessment bias, 
since the author performed both measurements. 
A third qualitative method that is commonly used to assess density by radiologists and is 
often reported on mammograms is the Breast Imaging Reporting and Data System (BI-
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RADS).56,57 In this method, four classes of density are reported: (1) breast is composed almost 
entirely of fat; (2) breast contains scattered fibroglandular densities; (3) breast is heterogeneously 
dense; and (4) breast is extremely dense.56 
The above mentioned methods are all qualitative as hence subject to a high-degree of 
subjectivity and low to moderate reproducibility. In one study, the intra-observer intraclass 
correlation coefficient (ICC) for the Wolfe patterns was reported as 0.68 and the inter-observer 
ICC as 0.65.58 The intra-rater reliability of the Tabar patterns was reported in one study as 
κ=0.65.59 These indicate good to moderate reliability. A study of inter-observer agreement of the 
BI-RADS method reported an overall reliability of κ=0.43, with extremely poor agreement for 
the “extremely dense” category (κ=0.17) and highest agreement for the “fatty” category 
(κ=0.76).60 
 
1.2.1.2 Quantitative Breast Density Measurements 
 
In order to reduce intra- and interobserved variability associated with Wolfe patterns and Tabar 
patterns, various methods have been developed to quantitatively assess mammographic 
parenchymal patterns.  
One of the first methods developed was the visual estimation of the proportion of the 
breast area occupied by dense tissue.61 Since then, planimetry, both manual and computerized, 
has been used to assess breast density. Planimetry involves tracing both the total breast area as 
well as areas of dense tissue (excluding biopsy scars, Cooper’s ligaments, and breast masses). 
The percent density is then calculated by dividing the area of the dense breast tissue by the total 
breast area. In manual planimetry, a wax pencil is used to trace the total area of the breast and all 
dense tissue areas onto a clear acetate sheet placed over the mammogram. A compensating polar 
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planimeter is then used to measure the total area of the breast and the area of breast density.62-64 
In computerized planimetry, digital mammograms or film mammograms that have been dititized 
are utilized. On a computer, a mouse is used to outline the total area of the breast as well as the 
dense areas and then the respective areas are calculated by the computer.65,66 The intra-reader 
reliability is high, with intra-class correlation coefficients reported as 0.97 for non-dense area, 
0.82 for absolute dense area, and 0.93 for percent density.66  
Another quantitative method is interactive thresholding. Using digitized images of the 
breast, the reader selects a “threshold brightness” to distinguish the breast tissue from the 
background of the mammogram. Then another “threshold brightness” is chosen that 
differentiates the dense and non-dense tissue. The computer uses these thresholds to identify both 
the total are of the breast as well as the areas of density. The number of pixels within these areas 
are summed to give a measure of the total breast area, the dense area, and the percent 
density.61,67-70 The intra-reader and inter-reader reliability using this computerized interactive 
thresholding method have been reported to be extremely high, with ICCs>0.90.70  
Similarly to Wolfe’s method, quantitative methods have shown an increased association 
(ORs ranging from 2.0-3.8).49,61,71  Finally, studies using both methods have verified these 
findings and indicate that quantitative methods are more strongly associated with breast cancer 
risk than Wolfe’s method.45,49,72 As can be seen, regardless of the method used breast density has 
been shown to be a strong risk factor for breast cancer in the general population.  
 
1.2.2 Breast Density and Mammographic Screening Sensitivity 
 
Breast density is one factor shown to affect mammographic sensitivity and specificity,73,74 and it 
is predictive of breast cancer risk.75-77  Higher density is associated with lower sensitivity and 
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specificity.78  Agents that affect breast density, therefore, also affect the mammographic 
screening success.  Breast density decreases with greater parity, greater body weight, and 
increased age,75 and increases with use of hormonal therapy (HT).79  For example, current use of 
HT, which increases breast density, is associated with a lower specificity (false-positive 
readings) and lower sensitivity (false-negative readings) of mammograms when compared with 
women not currently using HT.80 The estrogens and progestins present in the various HT 
combinations reversibly increase mammary cell proliferation.  This increase in mammary cell 
proliferation is observed on a mammogram as an increase in breast density and occurs in 17-37% 
of women on HT.81 If HT use is discontinued, the mammographic sensitivity is increased, 
decreasing the number of false-positives, and hence reducing the need to have a breast biopsy 
performed.80 Given this evidence, the current recommendation is that women on HT 
discontinued taking the medication 2 weeks prior to a mammogram.81  
 
1.2.3 Breast Density and Breast Cancer Risk 
 
The higher the breast density, the stronger the association with an increased risk of breast cancer.  
Comparing the highest category of breast density to the lowest, there is a 4- to 6-fold increased 
risk of breast cancer development.  A meta-analysis57 published in 2006 examined both 
qualitative and quantitative measures of breast density with breast cancer risk. The authors 
reported combined point estimates from general population prevalence studies using Wolfe 
patterns to be 1.25 (95% CI 1.02-1.54) for P1 versus N1, 1.97 (95% CI 1.29-3.00) for P2 versus 
N1, and 2.92 (95% CI 1.98-2.97) for DY versus N1. These point estimates were slightly higher 
for general population incidence studies (combined relative risks): 1.76 (95% CI 1.41-2.19) for 
P1 versus N1, 3.05 (95% CI 2.54-3.66) for P2 versus N1, and 3.98 (95% CI 2.53-6.27) for DY 
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versus N1.57 This meta-analysis did not include the one study that used the Tabar classification in 
its combined estimates. This study reported an increased risk of breast cancer among women 
with Tabar pattern IV (adjusted OR 2.42, 95% CI 0.98-5.97) when compared with Tabar pattern 
I.82  
In regards to studies that utilized quantitative measures of breast density, similar 
combined estimates of relative risk were observed in this meta-analysis. For general population 
prevalence studies, the authors reported combined relative risk estimates of 1.39 (95% CI 1.10-
1.76) for 5-24% density, 2.22 (95% CI 1.75-2.81) for 25-49% density, 2.93 (95% CI 2.27-3.79) 
for 50-74% density, and 3.67 (95% CI 2.72-4.96) for ≥75% density when compared with <5% 
density.57 Similarly, to the qualitative studies, the point estimates were slightly higher for general 
population incidence studies. The authors reported combined relative risks of 1.79 (95% CI 1.48-
2.16) for 5-14% density, 2.11 (95% CI 1.70-2.63) for 25-49% density, 2.92 (95% CI 2.49-3.42) 
for 50-74% density, and 4.64 (95% CI 3.64-5.91) for ≥75% density when compared to <5% 
density.57  
The meta-analysis referred to above by McCormack and dos Santos Silva57 illustrates the 
strong evidence for an association between breast density and breast cancer risk. Regardless of 
the methods used in the individual studies, whether qualitative or quantitative, or the type of 
study conducted, whether using incident or prevalent cases, similar and consistent results were 
obtained.  
Additionally, this meta-analysis57 illustrates the importance of masking bias when 
examining the association between breast density and breast cancer. Masking bias refers to the 
“masking” of breast cancer by high breast density. Tumors in dense tissue may be missed at an 
initial mammogram, but manifest themselves at subsequent mammographic examinations, thus 
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giving the appearance that women with higher density have an increased risk of breast cancer.83 
If masking bias is present, one would observe an underestimated relative risk in prevalence 
studies (cancers were detected at the time of screening) and an overestimated relative risk in 
incidence studies. This is exactly what the authors observed. The estimates for prelavence studies 
were lower than those of incidence studies. The authors also observed combined relative risks of 
4.64 (95% CI 3.64-5.91) for all cancers, 4.52 (95% CI 3.54-5.78) when cancers diagnosed in the 
first year were excluded, and 13.38 (95% CI 2.73-66.6) when including cancers diagnosed in the 
first year when comparing women with ≥75% density to those with <5% density.57 However, one 
could agree that since similar risk estimates where observed for both prevalence and incidence 
studies, that masking bias is not a major factor.75 From this meta-analysis the authors also 
concluded that the association between breast density and breast cancer risk remains strong 
regardless of age, menopausal status, or race.57  
Since the publication of the meta-analysis indicated above, only one additional article has 
been published that has examined the association between breast density and breast cancer risk. 
In this manuscript, Mitchell et al.84 reported that higher percent breast density remains a strong 
risk factor for breast cancer among women with known BRCA1/2 mutations. The odds of breast 
cancer among mutation carriers with density ≥50% were twice that of mutation carriers with 
<50% density (OR 2.29, 95% CI 1.23-4.26).84 
Changes in breast density have also been reported to be associated with subsequent 
changes in breast cancer risk. For each 1% increment in percent breast density an estimated 1.5-
2% increase in breast cancer risk occurs.75,85 This indicates that breast density is a stronger 
predictor of breast cancer risk than most traditional breast cancer risk factors. 
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1.2.4 Age, Menopausal Status and Breast Density 
 
Typically, breast density decreases with postmenopausal status and increasing age 71.  However, 
Byrne et al. 86 found a greater effect of breast density on breast cancer risk in postmenopausal 
women. Among premenopausal women, a woman with 1-24% breast density had an OR of 1.37 
(95% CI 0.95-2.3) and a woman with ≥75% breast density had an OR of 3.79 (95% CI 2.3-6.2) 
when compared to a premenopausal woman with 0% density. Similar increases in breast cancer 
risk with increasing breast density were observed for postmenopausal women, but the magnitude 
of the association was higher. A postmenopausal woman with 1-24% breast density had an OR 
of 1.79 (95% CI 1.3-2.5) and a woman with ≥75% breast density had an OR of 5.82 (95% CI 
3.0-11.3) when compared with a postmenopausal woman with 0% breast density.86 Similarly, 
Boyd et al.47 found a higher risk in women ages 50-59 with a RR 7.1 (95% CI 2.0-25.5) 
compared to women ages 40-49 RR 6.1 (95% CI 1.5-24.2).   
It appears that the menopausal transition has a stronger influence on breast density than 
age. Boyd et al.87 examined longitudinally the effects of menopause on breast density. The 
authors compared women who were premenopausal at a baseline mammogram and then 
postmenopausal at a subsequent mammogram to women who remained premenopausal at both 
mammograms, matched on age. The percent density decreased more among the women who 
transitioned through menopause as opposed to those who remained premenopausal.87 However, 
age may not be a factor in women over the age of 70 years. Modungo et al.88 examined 239 
participants from the Study of Osteoporotic Fractures (SOF) reported that only BMI, parity, 
surgical menopause, and current smoking status were significantly associated with 
mammographic breast density in multivariate analyses. The mean age of the women used for the 
study was 78.6 (SD 3.8). This indicates that factors associated with breast density may be 
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different in older women when compared with either premenopausal or younger postmenopausal 
women.88 
 
1.2.5 Breast Density and Breast Cancer Risk Factors 
 
In general, breast cancer risk factors are also associated with an increase in breast density. Early 
age at menarche, late age of menopause, nulliparity and later age at first full-term birth have been 
associated with increased density.89-95 Hormone therapy (HT) in the form of combined 
formulations of estrogen and progesterone increase density,79,96-102 while SERMS decrease 
density.76,103-105 Because the effects of both HT and SERMS on mammary cell proliferation are 
reversible, their respective effects on breast density cease with discontinuation of use. Changes 
in breast density are also observed among oral contraceptive users and by phase of the menstrual 
cycle. Breast density increases in premenopausal women during the luteal phase, which is 
characterized by elevated levels of estradiol.106-108 Because of the above-mentioned associations 
between reproductive and hormonal exposures and breast density, it has been hypothesized that 
mammographic breast density may be a marker of estrogen and other hormonal effects on the 
breast tissue.  
There is limited information on the relationship between circulating estradiol and breast 
density. Among postmenopausal women, not using exogenous hormones, one study found a 
positive association between estradiol levels and percent density; two studies found an inverse 
relationship; two found null relationahsips, one only after adjustment for sex hormone binding 
globulin (SHBG), age, and waist circumference.109-115 It has been suggested that localized 
estrogen production in the breast tissue may be more relevant to breast density than circulating 
estrogen levels. As with endogenous estrogens and breast density, the relationship between 
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breast density and bone mineral density, an established breast cancer risk factor and surrogate 
marker of estrogen exposure, remains unclear.114,115 
 Increased BMI is associated with an increased risk of breast cancer among 
postmenopausal women.  However, studies of mammographic breast density have consistently 
reported that increased weight or BMI is associated with lower percent breast density.59,66,94,116-
119 Vachon et al.94 observed a difference in percent density when the 3rd and 1st quartiles of BMI 
were compared – a 5.2 unit decrease among premenopausal women and a 4.7 unit decrease 
among postmenopausal women.  
The majority of studies examining the interaction between weight or BMI and breast 
density on the risk of breast cancer have noted significant effect modification. Ursin et al.85 
reported a U-shaped relationship, with women having the lowest and the highest BMI 
demonstrating the strongest association between breast density and risk of breast cancer. Duffy et 
al.120 reported that when evaluating the relationship between high-risk Tabar patterns and breast 
cancer risk, only those women who were both overweight and had dense breasts showed an 
increased risk of breast cancer (OR 2.30, 95% CI 0.98-5.40 for women with BMI >25 kg/m2 and 
dense breasts compared to those with BMI <25 kg/m2 and non-dense breasts). Boyd et al.121 also 
noted that BMI was not significantly associated with breast cancer in either pre- or 
postmenopausal women prior to adjustment for breast density. When percent breast density was 
controlled for, there was an increase and statistically significant association with breast cancer 
risk overall and for postmenopausal women. Although the association between BMI and breast 
cancer risk among premenopausal women increased, it was not statistically significant.121 The 
authors concluded that anthropometry and breast density are confounders of one another in 
relation to breast cancer risk and failure to adjust for breast density in previous studies may 
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explain the negative associations between BMI and breast cancer that are commonly reported 
among premenopausal women.121 
There may also be a genetic component to mammographic breast density. Boyd et al.122 
reported the results of two twin studies in women ages 40 to 70 years. The correlation 
coefficients for percent breast density were 0.61 for Australian monozygotic twins and 0.67 for 
North American monozygotic twins. For dizygotic twins, the correlation coefficients for percent 
density were 0.25 for Australian twins and 0.27 for North American twins. In these studies 
genetic factors explained 60-75% of the variability in percent breast density.122  
 
1.3 Prolactin 
 
Prolactin (PRL) is a 23kDa polypeptide protein with 199 amino acids arranged in four 
antiparallel α helices with three disulfide loops (Figure 2)123 and is located on chromosome 6.  Its 
amino acid sequence and tertiary structure is similar to both growth hormone and placental 
lactogen.124 Genes encoding all three growth factors evolved from a common ancestral gene by 
gene duplication. It is believed that the PRL and growth hormone lineages diverged 
approximately 400 million years ago.125 Along with growth hormone and placental lactogen, 
PRL has been classified as belonging to an extended family of proteins, known as the 
hematopoietic cytokines.126 Alternative splicing, proteolytic cleavage, phosphorylation, 
glycosylation, deamination of asparagines or glutamate residues, sulfonation of tyrosine residues, 
and polymerization and formation of complexes with other molecules result in a number of PRL 
variants.127 Aside from some limited research on proteolytic cleavage and phosphorylation of 
PRL, the physiological functions of the majority of these modifications are not yet known. What 
is known is that posttranslational modifications are often more harmful than helpful for the 
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activity of PRL – glycosylation lowers biological activity; phosphorylation generates PRL 
antagonisits; and proteolytic cleavage of PRL into 16KDa PRL abolishes receptor binding and 
has antiangiogenic properties.127,128 In addition, polymerization and conjugation to IgG can form 
large molecular species of PRL, such as “big” PRL (50-60 kDa) and macro-PRL (150-170 kDa) 
which are present in the serum of patients with hyperprolactinemia.123  
 
 
 
 
Figure 2:  Comparison of pituitary and extrapituitary prolactin (PRL) 
Notes: (a) Diagram of the gene encoding human PRL illustrating the proximal and superdistal 
promoter regions; (b) pituitary and extrapituitary transcripts; (c) PRL protein and the 
location of the three disulfide bridges. Note the use of exon 1a as the transcription start 
site for extrapituitary PRL and the longer 5′-untranslated region. Adapted from Ben-
Jonathan et al.123  
 
 
Prolactin is synthesized in and secreted by the lactotrophs – specialized cells of the 
anterior pituitary gland.124 Within the secretory granules of the lactotrophs, p21-activated protein 
kinase 2 (PAK2) mediates the phosphorylation of PRL.129 Phosphorylated PRL (pPRL) has both 
antagonistic and agonistic effects, as measured thru Nb2 lymphoma cells. These cells proliferate 
after treatment with lactogenic hormones and are often used to measure PRL activity.130,131 pPRL 
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inhibits the proliferation of Nb2 lymphoma cells in a dose-dependent, antagonistic manner.132 
However, a molecular mimic of pPRL (S179D) antagonizes PRL activity in Nb2 lymphoma 
cells.133 This mimic of pPRL also inhibits rat mammary gland growth134 and can antagonize PRL 
induced proliferation in breast cancer cell lines.135 Given the contrary roles of pPRL, much 
research is still needed in this area, as well as in the physiological functions of the various PRL 
variants.  
Although, pituitary PRL secretion can be either positively or negatively regulated, it is 
mainly controlled by inhibitory factors, such as dopamine, from the hypothalamus. The 
lactotrophs contains the D2 subclass of dopamine receptors which bind dopamine, thus inhibiting 
pituitary PRL secretion.124  The synthesis of pituitary PRL is driven by a proximal promoter, 
which is divided into a proximal region and a distal enhancer (Figure 2). Both of these are 
necessary for optimal pituitary-specific expression. The proximal promoter requires the Pit-1 
transcriptional factor for trans-activation and is regulated by dopamine, estrogens, neuropeptides 
and other growth factors.124  
Secondary secretion of PRL occurs at extrapituitary sites, such as the mammary 
epithelium, placenta, uterus, brain and the immune system.124 Because PRL can be synthesized 
in extrapituitary sites, it is considered a growth factor, as opposed to being classified as a 
hormone. Hormones are exclusively produced by endocrine glands and not by other cell types. 
The synthesis of extrapituitary PRL is driven by a superdistal promoter, located 5.8kb upstream 
of the pituitary start site (Figure 2). The superdistal promoter is silenced in the pituitary, does 
not bind the Pit-1 transcriptional factor and is not regulated by dopamine, estrogen or 
neuropeptides, unlike the pituitary PRL transcript.123 The alternative transcriptional start site, 
exon 1a, is spliced into exon 1b, thus yielding a coding region identical to the pituitary transcript. 
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However, since extrapituitary PRL is not stored in secretory granules it does not depend on Ca+2 
dependent exocytosis. Although, the superdistal promoter contains several binding sites for 
various transcription factors, its regulation is poorly understood. It is possible that these 
transcriptional factors are needed for the secretion of PRL at the various extrapituitary sites.  For 
example, progesterone decreases PRL synthesis in the myometrium, while increasing PRL 
synthesis in the endometrium.123  
 
1.3.1 Prolactin Receptor 
 
The prolactin receptor (PRLR) is a member of the class I cytokine receptor superfamily and is 
located on chromosome 5.136  It is a transmembrane receptor, consisting of an extracellular 
ligand-binding domain, a hydrophobic transmembrane domain, and an intercellular domain. 
Alternative splicing of the PRLR gene leads to multiple isoforms which differ in length and 
composition of their cytoplasmic tail, but have identical extracellular domains. Three different 
forms of the PRLR have been described – long form (90 kDa), intermediate form (50 kDa), and 
short form (40 kDa). The intermediate form is the result of a deletion mutant in the long form, 
resulting in the lack of 198 amino acids in the cytoplasmic tail. It is believed to be more sensitive 
to PRL than either the long or short forms of the receptor and is the predominant form found in 
Nb2 rat lymphoma cells.125 Both the long and intermediate forms are able to induce 
differentiation (measured by induction of milk protein gene expression), while the short form is a 
negative regulator of this differentiation. In the rat, the expression of the short and long PRLR 
isoforms have been shown to vary as a function of the stage of the estrous cycle, pregnancy, and 
lactation. The PRLR is not only capable of binding PRL, but PL (placental lactogen) and primate 
GH (growth hormone) as well.124 
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This receptor is virtually expressed in all organs and/or tissues, with its expression varies 
from very low (cells of the immune system) to ~200 to ~30,000 receptors per cell.124 
Interestingly, PRLR have been found in breast cancer cells. Mertani et al.137 found PRLR mRNA 
in normal breast, inflammatory lesions (mastitis), benign proliferative breast disease 
(fibroadenoma, papilloma, adenosis, epitheliosis), intraductal carcinoma or lobular carcinoma in 
situ, and invasive ductal, lobular, or medullary carcinoma. There was no correlation between the 
level of PRLR mRNA and the histological type of lesion. In another study, more than 90% of 
breast cancer surgical samples were also positive for PRLR mRNA.138 The cancerous tissue had 
significantly more mRNA than the adjacent, noninvolved tissue from the same patient. 
 
1.3.2 Activation of the Prolactin Receptor 
 
The extracellular domain of the PRLR consists of a NH2-terminal D1 sub-domain and a 
membrane-proximal D2 sub-domain, consisting of a total of 210 amino acids. The D1 sub-
domain is composed of two pairs of disulfide bonds between cysteine residues (Cys12-Cys22 and 
Cys51-Cys62), while the D2 sub-domain has a “WS motif” (Tryptophan-Serine-x-Tryptophan-
Serine), both of which are essential for proper folding and trafficking of the receptor to the cell 
membrane, but not ligand biding.125  
Prolactin (Figure 3) itself has two binding sites – binding site 1 (α helix 1 and 4) and 
binding site 2 (α helix 1 and 3). PRL binding site 1 binds with the D1 sub-domain of the PRLR. 
This initial interaction/binding then allows the same prolactin molecular to bind to another PRLR 
via binding site 2. This receptor dimerization is essential for the activation of a number of 
signaling cascades. It induces the phosphorylation of a tyrosine kinase, Janus kinase 2 (Jak2) that 
binds to the proline-rich box 1 motif of the intracellular domain of the PRLR. The activation of 
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Jak2 occurs approximately one minute after prolactin binding thru the transphosphorylation of 
two Jak2 molecules. However, this transphosphorylation can only occur if two conditions are 
met: (1) presence of a proline-rich box 1 motif; and (2) homodimeric stoichiometry of the ligand-
induced PRLR dimmers. Once the Jak2 kinases transphosphorylate one another, they then 
phosphorylate tyrosine residues (Y) in the PRLR itself.125  
 
 
 
 
Figure 3:  Prolactin Receptor Activation 
 
Mammary glands containing Jak2-/- epithelium in virgin animals develop normally, but 
the mammary glands fail to develop lobuloalveoli at parturition. The terminal end buds are 
present at the ends of ducts indicating an effect in the earlier stage of differentiation to alveolar 
buds. This phenotype is accompanied by a reduction in proliferation, maintenance of ductal cell 
markers and lack of secretory cell markers in Jak2-/- mammary epithelium.136,139  
The phosphorylation of the tyrosine residues of the PRLR by Jak2 allow signal 
transducer and activator of transcription (Stat) protein family members (Stat1, Stat3, Stat5) to 
bind to the prolactin receptor (Figure 4).125 The Stat family proteins contain five conserved 
regions: a DNA-binding domain, an SH3-like domain, an SH2-like domain, and a NH2- and 
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COOH-terminal transactivating domain. A phosphorylated tyrosine residue (Y) of the PRLR 
interacts with the SH2-like domain of Stat. This interacts causes the Stat to dock at the PRLR, 
leading to its activation by Jak2. Once the Stat is phosphyrated, it then dissociates from the 
PRLR and either hetero- or homodimerizes through its phosphorylated tyrosine residues with the 
SH2-like domain of another phosphorylated Stat molecule. The Stat dimmer is then able to 
translocate to the nucleus where it activates a Stat DNA-binding motif  (GAS – γ-interferon 
activated sequence with a palindromic sequence of TTCxxxGAA) in the promoter of the 
prolactin gene to initiate gene transcription.140 Aside of prolactin, Stat is also able to interact with 
other signal transducers to initiate a cell- and/or cytokine-specific response. The above activation 
occurs in the long-form of the prolactin receptor. The tyrosine residues of the short PRLR are not 
phosphorylated by Jak2, but the phosphotyrosine of Jak2 serves as a docking site for Stat1.125 
Lack of Stat5 in mice lead to impaired mammary gland development due to a reduced 
formation of lobuloalveoli.141 Stat5-/- mammary epithelium develop normally in virgin animals 
but lack lobuloalveolar development at parturition, demonstrating a role for Stat5 in mammary 
gland development.141 This phenotype may be more extreme than the PRLR-/- mammary 
phenotype due to presence of a closed epithelial lumen and aberrant cell-cell contacts. Stat5 -/- 
epithelium retains markers of ductal epithelium and fails to express markers of secretory 
epithelium.142 The PRLR -/- mammary epithelium has a greater defect in proliferation in 
response to estrogen and progesterone than the Stat5-/- mammary epithelium, indicating that 
Stat5 mediates the effect of PRL on differentiation, but not proliferation.142 However, other 
hormones and growth factors are able to stimulate Stata5 activation. GH and epidermal growth 
factor are able to stimulate Stata5 activation in PRLR -/- mammary epithelium.142  
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Figure 4:  Signal transduction pathways initiated by activation of the prolactin receptor 
(PRLR)
 
 
The tyrosine phosphorylation sites in the PRLR also serve as docking sites (Figure 4) for 
the adapter proteins Src homoly 2 domain containing transforming protein (Shc), growth factor 
receptor bound protein 2 (Grb2) and son of sevenless (SOS).125 Binding of these proteins result 
in the activation of Ras and Raf, which in turn activate the mitogen activated  protein (MAP) 
kinase pathway.125,136 Activation of the MAP kinase pathway is believed to mediate the effect of 
prolactin on the proliferation of mammary epithelial cells.143 In addition, the PRLR also 
facilitates docking of Src family kinases, c-src and Fyn. These kinases can then activate protein 
kinase B and the phosphatidylinositol 3’-kinase (PI3 kinase) pathway.144 Activation of the PI3 
kinase pathway is believe to regulate prolactin’s anti-apoptotic and cell proliferation effects.145  
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Additionally, box 1 of the intracellular domain of the prolactin receptor is involved in the 
activation of a tyrosine kinase-dependent, calcium-sensitive K+ channels through Jak2. The 
COOH terminal of the PRLR’s intracellular domain is involved in the production of the 
intracellular messengers inositol 1,3,4,5-tetrakisphosphate (IP4) and inositol 
hexakisphosphosphate (IP6), which open voltage-independent Ca+2 channels in the cell 
membrane (Figure 4).125 These Ca+2 channels are regulated by dopamine released from the 
hypothalamus, acting as a prolactin release-inhibiting factor.146 Dopamine can activate several 
interacting intracellular signaling pathways to suppress PRL gene expression and lactrotroph 
proliferation.147  
 
1.3.3 Downregulation of the Prolactin Receptor 
 
Reduction of PRLR signaling is mediated by members of the suppressor of cytokine signaling 
(Socs) gene family. For example, Socs1 and Socs3 are activated thru the inhibition of the 
Jak/Stat pathways.148 Socs1-/- mice exhibit accelerated lobuloalveolar development 
characterized by an increase in lobuloalveoli, enlargement of the lumen, an increase in milk 
protein expression, and Stat5 phosphorylation during pregnancy and lactation. Deletion of a 
single Socs1 allele is able to restore lobuloalveolar development in PRL +/- mammary 
epithelium, demonstration that Socs1 is a key regulator of PRL signaling in the mammary 
gland.149  
 
1.3.4 Pathologies Associated with Prolactin 
 
Prolactinoma is a tumor of the pituitary gland, accounting for 25-30% of functioning pituitary 
adenomas150 and is the most frequent cause of persistent hyperprolactinaemia – defined as the 
 29 
 
presence of an abnormally high level of prolactin in the blood; normal levels for non-pregnant 
women are typically 20-25 ng/mL and for pregnant women, prolactin levels can reach 500 
ng/mL.151 In premenopausal women, hyperprolactinaemia may manifest itself as galactorrhea, 
oligomenorrhea, loss of libido, and sexual dysfunction. Prolactinomas in premenopausal women 
tend to be microprolactinomas (<10 mm in diameter).152 In contrast, prolactinomas in 
postmenopausal women tend to be macroprolactinomas (>10 mm in diameter).152 In addition to 
having hyperprolactinaemia, postmenopausal women may also experience headache, visual 
disturbances, cranial nerve palsies, hypopituitarism, or rarely spontaneous cerebrospinal fluid 
leakage, epilepsy due to temporal lobe compression and obstructive hydrocephalus.152   
Aside from prolactinomas, certain medications can also cause hyperprolactinaemia. 
These include anti-psychotics (phenothiazines, haloperidol, butyrophenones, risperidone, 
monoamine oxidase inhibitors, fluoxetine, sulpiride), anti-emetics (metoclorpramide, 
domperidone), anti-hypertensives (methyldopa, calcium channel blockers, reserpine), and 
tricyclic depressants that inhibit the release of dopamine.150 In addition, certain opiates can 
stimulate hypothalamic opioid receptors that promote prolactin secretion and protease inhibitors 
increase prolactin levels via unknown mechanisms.150  
Treatment of prolactinomas usually involves dopamine agonists. Dopamine is an 
inhibitor of PRL, regulating prolactin gene expression and lactrotroph proliferation.  Dopamine 
receptors are classified into D1 and D2 sub-types. Aside from both receptor sub-types being 
found in the brain (susbstantia nigra and striatum, and limbic cortex and associated structures), 
the D1 sub-type is also found in blood vessels and the proximal tubule cells, while the D2 sub-
type is found on the cell surface of lactotroph cells and in the sympathetic nerve terminals.147 
The dopamine agonists, bromocriptine, cabergoline (Dostinex®, Pfizer, Inc., New York, USA), 
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and quinagolide (Norprolac®, Ferring Pharmaceuticals, Lausanne, Switzeralnd) have a high-
affinity for the D2 receptor sub-types on the lactotroph cells of the anterior pituitary and act to 
reduce prolactin secretion147,150.  
 
1.3.5 Circadian Rhythm of Prolactin Secretion 
 
Sassin et al.153 in 1972 measured plasma prolactin levels at 20-minute intervals for a 24-hour 
period in normal adults. They were also to demonstrate that prolactin levels “undergo episodic 
changes and there is a diurnal variation in release, with highest concentrations during the 
nocturnal sleep period and the lowest during the waking hours.” Since this initial report, other 
researchers have demonstrated that prolactin levels begin to rise as one falls asleep and reach a 
maximum 1-2 hours before waking, with peaks of prolactin secretion occurring during slow-
wave sleep. This rhythm changes if the sleep pattern is disturbed or rearranged.146,154  
 
1.3.6 Polymorphisms in the Prolactin Gene and Prolactin Receptor Gene 
 
Recent studies have established an immuno-regulatory function for prolactin.155-157 Prolactin is 
not only produced by the anterior pituitary gland, but at various extrapituitary sites, including T 
lymphocytes. The prolactin receptor is a member of the class I cytokine receptor superfamily, 
suggesting that PRL may have a multifunctional cytokine role in addition to its endocrine role. 
Prolactin, acting through its receptor, stimulates cell proliferation and survival,158 hence 
modulating the function of the immune system.  Additional proof for the role of PRL in the 
immune system comes from animal models, in which ablation of the pituitary gland or treatment 
with bromocriptine (a dopamine agonist that reduces pituitary PRL release) induced anemia, 
leucopenia and thrombocytopenia, as well as an impaired humoral and cellular immune 
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response.159,160 In all of these studies, the lympho-hemopoietic function was restored when either 
PRL was injected or a syngenic pituitary gland was implanted.159,160  Studies in patients with a 
deficient immune system, including individuals with systemic lupus eythematosus,161,162 multiple 
sclerosis,163 rheumatoid arthritis,164 Reiter’s disease,165 Sjogren’s syndrome,166 Hashimoto’s 
thyroiditis,167 and uveitis,168 have found moderately increased levels of PRL. In addition, genetic 
studies have confirmed that PRL maps to chromosome 6p, and is telomeric to the HLA region.155  
The HLA region has been linked to autoimmune diseases, most notably type 2 diabetes mellitus.  
Several SNPs have been identified in the PRL gene. These include -1149 extrapituitary 
promoter G/T (rs1341239);156,157,169 -733 extrapituitary promoter C/T;156 -328 pituitary promoter 
G/A;156 +78 exon 5 G/A;156 and +214 intron C T/C (rs7739889).156 However, the study 
populations used to identify these SNPs have had a deficient immune system.156,157,161-169  
Only one study to date has examined the association between SNPs in the PRL and 
PRLR gene with breast cancer risk. Vaclavicek et al.170 conducted a case control study of 441 
German familial unrelated breast cancer cases and 552 hospital-based controls matched by age, 
ethnicity, and geographical region. Although women carrying BRCA1/2 mutations were 
excluded, all cases had a strong family history of breast cancer – 131 cases with two or more 
breast cancer cases in the family, with at least two cases with onset before 50 years of age; 68 
cases with at least one breast cancer and one ovarian cancer in the family; 201 cases with at least 
two breast cancer cases in the family, not meeting the above two criteria; 16 cases with a single 
breast cancer case in the family diagnosed before the age of 15 years; 3 cases with both female 
and male breast cancer in the family; 13 cases with bilateral breast cancer diagnosed before the 
age of 50 years; and 9 cases with missing family history. A total of 7 SNPs were selected for 
genotyping. Within the PRL gene, the SNPs chosen were rs1341239, rs12210179, rs2244502, 
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and rs1205960. Two SNPs (TT for rs1341239 and GG for rs12210179) were statistically 
significantly associated with a higher breast cancer risk (OR 1.67, 95% CI 1.11-2.50, and OR 
2.09, 95% CI 1.23-3.52, respectively). When haplotypes where constructed from the four SNPs 
listed above, in the order listed, the TGTG haplotype was also statistically significantly 
associated with a higher breast cancer risk (OR 1.42, 95% CI 1.07-1.90). For the PRLR gene, 
three SNPs were chosen - rs13354826, rs9292573, and rs37389. None were statistically 
associated with an increased breast cancer risk, but interestingly the TCC haplotype conferred a 
statistically significant reduction in breast cancer risk (OR 0.69, 95% CI 0.54-0.89).170  
No study to date has identified PRL and PRLR SNPs in a healthy population without a 
comprised immune system. Also, the functional significance of PRL and PRLR SNPs has not yet 
been established nor have the various SNPs been correlated with serum prolactin levels. 
 
1.3.7 Effect of Prolactin and Prolactin Receptor on the Mammary Gland: Animal Studies 
 
In wild-type animals ductal elongation results from the formation of terminal end buds (TEBs) – 
specialized structures with high rates of cell division at their invasive leading edge and a central 
zone of apoptotic cells that produce the canalized duct. This structure differentiates into a 
terminal alvelolar bud once ductal elongation has terminated. In mammary glands from prolactin 
receptor gene deficient (PRLR-/-) mice, ductal elongation occurs normally as the animals enter 
puberty, however secondary side branching does not occur as the animals age and the ducts 
become more distended.171,172 In mature PRLR-/- animals, the TEB-like structure lacks the cap 
cell layer and the multiple layers of highly mitotic and apoptotic cells. This suggests a defect in 
the final stage of differentiation.171  
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Transplantation of PRLR-/- mammary epithelium to the mammary fat pad of an immuno-
compromised but otherwise normal animal allows examination of PRLR-/- mammary gland 
development in a normal endocrine environment, thus allowing development during pregnancy 
to be examined. The host fat pad is cleared of endogenous epithelium and the transplanted 
epithelium is allowed to penetrate and fill the fat pad.136 Transplanted PRLR-/- epithelium 
develop side branches in virgin animals, as the epithelium experiences normal levels of sex 
steroid hormones. During pregnancy, a complete failure of lobuloalvelolar development is 
observed and only alveolar-buds are formed. This implicated PRLR in mediating the formation 
of milk producing structures during pregnancy.171  
In order to form functional lobuloaveoli during pregnancy, two processes must occur 
within the alveolar bud. The first is proliferation to increase cell number to provide greater 
epithelial surface area for milk production and secretion (lobuloalveolar development). The 
second process is final stage differentiation to allow the cells to produce and secrete milk 
(lactogenesis). Both processes require the activation of the PRLR.136  PRLR-/- epithelium do not 
proliferate to form lobuloalveoli in transplants171 or after treatment with estrogen and 
progesterone.173 However, in PRLR+/- mice lack of proliferation is only observed at the later 
lactogenesis stage, indicating a defect in differentiation. In addition, PRLR +/- mice mated at 8 
weeks of age have less than a 50% chance of successfully nursing their young, although these 
mothers have a greater chance of successful lactation following their second pregnancy. The 
mammary glands of these mothers who fail to lactate show the formation of lobules, but they are 
unable to form an open lumen or secrete milk – their development is stopped at mid-
pregnancy.174 The PRLR +/- phenotype suggests that the level of signaling flux initiated by PRL 
can modulate mammary gland development, with the later developmental stage of lactogenesis 
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requiring higher levels of PRLR signaling that cannot be met from a single functional PRLR 
allele.174 
PRL produced by the mammary gland may also play a role in proliferation of mammary 
epithelial cells during lactogenesis. PRL -/- mammary epithelium transplanted to a wild-type 
cleared mammary fat pad showed a decrease in proliferation. This indicates that mammary-
produced PRL has a role in sustaining milk production, rather than development of the gland 
during pregnancy.136  
 
 
1.3.8 The Role of Prolactin in Breast Development 
 
Unlike most organs in women, the mammary gland completes its development postnatally at 
three distinct points in a woman’s life: during puberty, throughout pregnancy and during 
lactation.175,176 The exact mechanisms linking these events to breast development remain 
unknown, but estrogen is believed to play a major role.  There is, however, much evidence 
linking prolactin to breast development as both a mitogen and differentiating agent,138,177 
especially during pregnancy and lactation.  During pregnancy, breast epithelial cells rapidly 
proliferate to create additional ductal branches and promote lobuloalveolar growth.178  Prolactin 
has been shown to act directly on the mammary epithelium to produce lobuloalveolar 
development.171 Although, estrogen and progesterone are also involved in ductal growth and 
branching, PRL is essential for full lobuloalveolar development. Progesterone appears to 
increase the level of PRLR, thus acting synergistically with prolactin to exert its effects on ductal 
growth and lobuloalveolar development.179 If PRL is absent during puberty, the mammary gland 
is underdeveloped. Additional during lactation, the alveoli serve as the unit of milk production 
and are directly under the control of circulating PRL.  Upon ceasing lactation, PRL levels drop 
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causing the mammary gland to undergo extensive restructuring and apoptosis leading to 
involution and a return to the primary ductal structure.180   
 
1.3.9 Prolactin as a Risk Factor for Breast Cancer: Epidemiologic Studies 
 
There have been several case/control studies181-186  examining the breast cancer – prolactin 
association with inconsistent findings (Table 2).  Small studies of postmenopausal women, 
ranging in size from 12 to 48 cases, have reported a significant positive association184,186   or a 
significant negative association.183  Six small studies of pre-menopausal women, ranging in size 
from 6 to 66 cases, have reported positive183,184,187  and no association.186,188,189 Three studies in 
which menopausal status was not evaluated reported no significant associations.181,182,185  Small 
sample size and the use of post-diagnostic PRL levels, which may be affected by the presence of 
a tumor, likely explain these contradictory findings. 
 Several small (21-71 cases) prospective studies (Table 3) have failed to find any positive 
association between PRL levels and subsequent breast cancer.144,190-192  Similarly, two small 
prospective studies190,191  failed to find a significant association with post-menopausal disease, 
although in both studies, the relative risk was elevated, suggesting a positive association. The 
Nurses Health Study193  has reported a significant positive association for post-menopausal 
disease (RR 2.03, 95% CI 1.24-3.31, highest versus lowest quartile). The association was 
stronger when cases were limited to invasive disease (RR 2.64, 95% CI 1.54-4.51), and it was 
not altered when adjusted for circulating estrogens, androgens and IGFs.  Using some of the 
same cases and controls from the Nurses Health Study, Tworoger et al.194 examined the 
association between plasma prolactin concentrations and breast cancer risk. A significant 
positive association was also found in this study of postmenopausal women (RR=1.34, 95% CI 
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1.02-1.76, highest versus lowest quartile of prolactin concentrations). The association was 
stronger when limited to invasive breast cancer (RR=1.41, 95% CI 1.08-1.86), for tumors >2 cm 
(RR=1.66, 95% CI 1.04-2.64), and for ER+/PR+ tumors (RR=1.78, 95% CI 1.28-2.50).194 The 
estrogen receptor (ER) and PRLR appear to be co-expressed (through an unknown 
mechanism),195 but previous studies have not observed any association between the two 
receptors.26,183,196  This positive relationship between PRL and post-menopausal breast cancer is 
similar in magnitude to that recently observed in a pooled analysis of nine prospective studies for 
estrogen and breast cancer  (RR 2.0, 95% CI 1.47-2.71, highest versus lowest quartile).26 These 
findings need to be validated in other populations. 
 Tworoger et al.197 in a follow-up study of the Nurses’ Health Study II, observed a 
positive association between prolactin and breast cancer risk (RR 1.5, 95% CI 1.0-2.5, highest 
versus lowest quartile) among premenopausal women. The observed association was stronger 
when the sample was restricted to women diagnosed with ER+/PR+ breast cancer (RR=1.9, 95% 
CI 1.0-3.7). The estrogen receptor (ER) and PRLR appear to be co-expressed (through an 
unknown mechanism),195 but previous studies have not observed any association between the 
two receptors.26,183,196 These initial data suggest that prolactin may be involved in the 
development of ER+ tumors, although further studies are needed to confirm this observation.  
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Table 2:  Case-Control Studies of Prolactin and Breast Cancer Risk 
 
Study Description Blood 
Collection 
Menopausal 
Status 
Cases/Controls Comparison Odds Ratio (95% CI) 
 
Wilson et 
al. 1974 181 
Hospital-based Collected in the 
late afternoon 
Not Evaluated 14 primary breast cancer 
18 localized advanced BC 
13 metastatic breast cancer 
39 controls 
Mean prolactin level 
(mamp/ml) 
10.86 ± 2.20 
  8.44 ± 0.99 
  7.69 ± 1.64 
  8.31 ± 1.16 
Sheth et al. 
1975 182 
Tata Medical 
Hospital 
Collected at 
intervals of 48 
hours during the 
7th to 23rd day of 
menstrual cycle 
Premenopausal; 
Postmenopausal 
Breast cancer cases 
  42 – ages 31-40 
  30 – ages 42-50 
  26 – ages 51-60 
12 Cystic mastitis 
10 gynaecomastia 
 
Premenopausal 
   10 – follicular phase 
     8 – luteal phase 
12 Postmenopausal  
Mean serum prolactin 
level (ng/ml) 
 
22 ± 3 
19 ± 2 
17 ± 2 
14 ± 2 
16 ± 2 
 
 
21 ± 4 
43 ± 5 
20 ± 3 
Malarkey, 
et al. 1977 
183 
 Hourly blood 
collection 
Premenopausal; 
Postmenopausal 
Pre follicular phase 
  1 breast cancer case 
  5 benign breast disease 
  7 controls 
Pre luteal phase 
  5 breast cancer cases 
  7 benign breast disease 
  9 controls 
Postmenopausal women 
 12 breast cancer cases 
   4 benign breast disease 
   9 controls 
Matched on age and weight 
 
Mean nocturnal 
(12pm-7am) serum 
PRL levels (ng/ml) 
 
 
Pre follicular phase 
19.8 ± 1.9 
19.8 ± 3.5 
15.9 ± 1.7  
Pre luteal phase 
23.5 ± 2.6 
22.5 ± 2.8 
19.1 ± 0.9  
Postmenopausal 
  9.3 ± 0.9 
11.4 ± 2.1 
13.4 ± 1.3 
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Table 2 (Continued) 
 
Study Description Blood 
Collection 
Menopausal 
Status 
Cases/Controls Comparison Odds Ratio (95% CI) 
 
Rose et al. 
1981 184 
 Collected 
between 7-9am 
with subjects in a 
resting state 
Premenopausal; 
Postmenopausal 
Premenopausal 
  14 premastectomy BC cases 
  21 postmastectomy BC cases 
    9 advanced BC cases 
  34 controls 
 
Postmenopausal 
 20 premastectomy BC cases 
 17 postmastectomy BC cases 
 29 advanced BC cases 
 39 controls 
 
Overall 
18 premastectomy BC cases 
20 postmastectomy BC cases 
23 advanced BC cases 
18 controls   
Plasma prolactin 
levels (ng/ml) 
Premenopausal 
22.9 ± 32.4 (p<0.001) 
32.6 ± 25.3 (p<0.001) 
11.4 ± 2.8 
  9.1 ± 3.6 
 
Postmenopausal 
13.5 ± 15.9 (p<0.001) 
27.2 ± 31.2 (p<0.001) 
15.6 ± 15.6 (p<0.001) 
  4.9 ± 2.2 
 
Overall 
21.9 ± 31.4 (p<0.001) 
30.2 ± 27.8 (p<0.001) 
16.5 ± 15.2 (p<0.001) 
  6.8 ± 3.6 
Meyer et al. 
1986 187 
Caucasian; 
1978-1981; 
8 institutions 
in Boston 
SMSA 
Luteal phase 
blood collection 
Premenopausal <140 mU/liter – Reference 
    6 breast cancer cases 
  25 controls 
140-240 mU/liter 
  11 beast cancer cases 
  53 controls 
>240 mU/liter 
  19 breast cancer cases 
  25 controls 
>500 mU/liter (above upper 
limit of normal range) 
  6 breast cancer cases 
  2 controls  
Plasma levels <140 mU/liter 
 RR = 1.0 
 
140-240 mU/liter 
RR = 0.8 (95% CI 0.2-2.5) 
 
>240 mU/liter 
RR = 2.7 (95% CI 0.9-8.5) 
 
>500 mU/liter 
RR = 11.9 (95% CI 1.6-
90.1) 
 
 39 
 
Table 2 (Continued) 
 
Study Description Blood 
Collection 
Menopausal 
Status 
Cases/Controls Comparison Odds Ratio (95% CI) 
 
Anderson et 
al 1989 185 
Family History 
Breast Cancer 
Clinic 
Collected 
between 10am 
and 3pm 
Premenopausal; 
Postmenopausal 
Familial breast cancer 
  67 cases 
  55 controls 
Premenopausal familial 
  39 cases 
  43 controls 
Matched breast cancer cases 
and controls 
  20 cases 
  20 controls 
Matched by age, parity, 
weight, menopausal status 
Median PRL levels 
(ng/ml) 
Familial breast cancer 
  Cases = 7.8 
  Controls = 7.9 
Premenopausal familial 
   Cases = 8.1 
   Controls = 7.8 
Matched sample 
   Cases = 9.9 
   Controls = 6.9 
 
All associations were 
statistically non-significant 
Ingram et 
al. 1990 186 
Western 
Australia; 
1985 to 1987 
Fasting blood 
sample collected 
between 8am and 
12 noon; 
collected on day 
21 or 22 of 
menstrual cycle 
for 
premenopausal 
women 
Premenopausal; 
Postmenopausal 
Benign fibrocystic dx 
   86 cases 
 102 controls 
Benign epithelial hyperplasia 
of the breast 
   82 cases 
 101 controls 
Breast cancer 
   78 cases 
 122 controls 
Matched by age & residence 
Mean prolactin levels Benign fibrocystic dx 
OR=1.03 (95% CI 0.59-1.80) 
Benign epithelial 
hyperplasia of the breast 
OR =1.70 (95% CI 0.89-3.27) 
Breast cancer 
OR=2.12 (95% CI 1.00-4.51) 
Premenopausal BC 
RR=1.56 (95% CI 0.56-4.29) 
Postmenopausal BC 
RR=3.57 (95% CI 1.16-11.02) 
Love, et al. 
1991 188 
Caucasian; 
from upper 
Midwest US 
Between 8-9am 
on day 22±2 of 
their cycle; 1-2 
hours after 
awakening 
premenopausal 18 cases w/ mastectomy (BC); 
23 controls with a strong 
family hx of breast cancer 
(FH); 
39 controls with no family hx 
(Controls) 
Mean serum PRL 
RIA levels (log 
transformed levels) 
Parous women (p=0.94) 
BC  mean = 2.18 
FH  mean = 2.24 
Controls mean = 2.24 
Nulliparous women: 
(p=0.41) 
BC mean = 2.59 
FH mean = 2.89 
Controls mean = 2.61 
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Table 3:  Prospective Studies of Prolactin and Breast Cancer Risk 
 
Study Description Blood 
Collection 
Menopausal 
Status 
Cases/Controls Comparison Relative Risk (95% CI) 
 
Wang et al 
1992 190 
Island of 
Guernsey; 
1968 to 1976 
Collected at time 
of enrollment 
Premenopausal; 
Postmenopausal 
Premenopausal women 
I – 14 cases; 9903 person-yrs 
II – 11 cases; 10314 person-yrs 
III – 10 cases; 10062 person-yrs 
IV – 19 cases; 9764 person-yrs 
V – 17 cases; 9898 person-yrs 
 
Postmenopausal women 
I – 6 cases; 4526 person-yrs 
II – 6 cases; 4521 person-yrs 
III – 11 cases; 4510 person-yrs 
IV – 8 cases; 4412 person-yrs 
V – 9 cases; 4391 person-yrs 
Serum 
prolactin 
levels (ng/ml) 
Quintiles of Prolactin 
 
Premenopausal women 
I – RR=1.00 
II – RR=0.70 (95% CI 0.31-1.56) 
III – RR=0.67 (95% CI 0.29-1.53) 
IV – RR=1.25 (95% CI 0.62-2.55) 
V – RR=1.07 (95%CI 0.51-2.23) 
 
Postmenopausal women 
I – RR=1.00 
II – RR=1.05 (95% CI 0.33-3.34) 
III – RR=1.83 (95% CI 0.66-5.06) 
IV – RR=1.32 (95% CI 0.45-3.92) 
V – RR=1.63 (95% CI 0.57-4.71) 
 
Adjusted for age, parity, height, 
and hx of benign dx 
Helzlsouer 
et al. 1994 
192 
Follow-up 
Washington 
County 
Cohort; 1974 
to 1991 
 Premenopausal 21 incident breast cancer cases 
not on oral contraceptives or  
HRT 
42 controls 
Serum 
prolactin 
levels (ng/ml) 
Matched OR by tertiles 
 
Low OR=1.0 
 
Med OR=0.6 (95% CI 0.1-2.5) 
 
High OR=1.1 (95% CI 0.3-4.1) 
 
Matched for age, parity, height, 
benign breast dx 
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Table 3 (Continued) 
 
Study Description Blood 
Collection 
Menopausal 
Status 
Cases/Controls Comparison Relative Risk (95% CI) 
Hankinson 
et al. 1999 
193 
Follow-up of 
the Nurses’ 
Health Study; 
1989 to 1994 
Collected at time 
of enrollment  
Postmenopausal All women 
  306 breast cancer cases 
  448 controls 
Quartiles of 
plasma 
prolactin level 
(ng/ml) 
All women: 
I – RR=1.0 
II – RR=1.05 (95% CI 0.65-1.71) 
III – RR=1.45 (95% CI 0.91-2.31) 
IV – RR=2.03 (95% CI 1.24-3.31) 
Invasive breast cancer: 
I – RR=1.0 
II – RR=1.26 (95% CI 0.75-2.13) 
III – RR=1.61 (95% CI 0.98-2.64) 
IV – RR=2.64 (95% CI 1.54-4.51) 
Excluding first 2 yrs of follow-
up: 
I – RR=1.0 
II – RR=0.69 (95% CI 0.37-1.32) 
III – RR=1.34 (95% CI 0.72-2.51) 
IV – RR=2.39 (95% CI 1.24-4.61) 
 
Adjusted for BMI at age 18 yrs, 
family history of breast cancer, age 
at menarche, age at first 
birth/parity, age at menopause, 
duration of postmenopausal 
hormone use, month & time of 
blood draw, fasting  
Kabuto et 
al 2000 191 
Life Span 
Study  Pop of 
the Radiation 
Effects 
Research 
Foundation in 
Hiroshima & 
Nagasaki, 
Japan; follow-
up from 1970 
to 1983 
Collected 
between 1968 
and 1970 
Premenopausal; 
Postmenopausal 
Premenopausal women 
  46 cases 
  94 controls 
 
Postmenopausal women 
  26 cases 
  56 controls 
Unit increase 
in log10 of 
serum 
prolactin 
levels  
All 
OR=1.76 (95% CI 0.02-43.9) 
Premenopausal 
OR=1.01 (95% CI 0.02-47.4) 
Postmenopausal 
OR=6.45 (95% CI 0.01-43.9) 
 
Matched on age, date of blood 
collection, exposure, radiation 
dose, and city 
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Table 3 (Continued) 
 
Study Description Blood 
Collection 
Menopausal 
Status 
Cases/Controls Comparison Relative Risk (95% CI) 
Tworoger 
et al. 
2004194 
Nurses’ Health 
Study; 1989-
2000 
Collected 
between 1989 
and 1990 
Postmenopausal All postmenopausal women: 
851 cases; 1,275 controls 
 
 
Invasive breast cancer: 
722 cases 
 
Ductal breast cancer: 
588 cases 
 
Lobular breast cancer: 
93 cases 
 
Tumor size ≤2 cm: 
531 cases 
 
Tumor size >2 cm: 
162 cases 
 
ER+/PR+ breast cancer: 
397 cases 
 
ER-/PR- breast cancer: 
96 cases 
 
ER+/PR- breast cancer: 
91 cases 
 
Matched on age, 
postmenopausal hormone use, 
fasting status & time of day and 
month of blood collection 
 
Quartiles of 
plasma 
prolactin level 
(ng/ml) 
RR comparing quartile IV to I 
All postmenopausal women: 
RR=1.34 (95% CI 1.02-1.76) 
 
Invasive breast cancer: 
RR=1.41 (95% CI 1.08-1.86) 
 
Ductal breast cancer: 
RR=1.38 (95% CI 1.04-1.85) 
 
Lobular breast cancer: 
RR=1.76 (95% CI 0.95-3.26) 
 
Tumor size ≤2 cm: 
RR=1.35 (95% CI 1.00-1.83) 
 
Tumor size >2 cm: 
RR=1.66 (95% CI 1.04-2.64) 
 
ER+/PR+ breast cancer: 
RR=1.78 (95% CI 1.28-2.50) 
 
ER-/PR- breast cancer: 
RR=0.76  (95% CI 0.43-1.32) 
 
ER+/PR- breast cancer: 
RR=1.94 (95% CI 0.99-3.78) 
 
Adjusted for BMI at age 18 yrs, 
weight change from age 18 to 
blood draw, family history of 
breast cancer, age at menarche, age 
at first birth/parity, age at 
menopause & matching factors 
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Table 3 (Continued) 
 
Study Description Blood 
Collection 
Menopausal 
Status 
Cases/Controls Comparison Relative Risk (95% CI) 
Tworoger 
et al. 
2006197 
Nurses’ Health 
Study II; 1996 
to 1999 
Collected 
between 1996 
and 1999  
Premenopausal  
All premenopausal women: 
All – 235 cases; 470 controls 
Invasive – 159 cases; 318 controls 
ER+/PR+ – 109 cases; 218 controls  
 
T1 – 86 cases; 172 controls 
T2 – 79 cases; 158 controls 
T3 – 70 cases; 140 controls 
 
Follicular phase prolactin: 
All – 193 cases; 386 controls 
Invasive – 130 cases; 260 controls 
ER+/PR+ – 89 cases; 178 controls  
 
T1 – 63 cases; 126 controls 
T2 – 64 cases; 128 controls 
T3 – 66 cases; 132 controls 
 
Luteal phase prolactin: 
All – 197 cases; 394 controls 
Invasive – 131 cases; 262 controls 
ER+/PR+ – 89 cases; 178 controls  
 
T1 – 63 cases; 126 controls 
T2 – 66 cases; 132 controls 
T3 – 68 cases; 136 controls 
 
Matched on age, fasting status, 
time of day & month of blood 
collection, race/ethnicity, and 
timing of blood draw within the 
menstrual cycle 
Quartiles of 
plasma 
prolactin level 
(ng/ml) 
& 
time between 
blood draw 
and breast 
cancer 
diagnosis 
T1 - <2 yrs; 
T2 – 2 yrs to 
<3.875 yrs; 
T3 – ≥3.875 
yrs 
RR comparing quartile IV to I 
All premenopausal women: 
All cases – RR=1.5 (95% CI 1.0-2.5) 
Invasive  – RR=1.6 (95% CI 0.9-2.7) 
ER+/PR+ – RR=1.9 (95% CI 1.0-3.7) 
 
T1 - RR=1.6 (95% CI 0.8-3.0) 
T2 – RR=1.8 (95% CI 0.9-3.5) 
T3 – RR=1.1 (95% CI 0.5-2.3) 
 
Follicular phase prolactin: 
All cases – RR=1.3 (95% CI 0.8-2.1) 
Invasive  – RR=1.3 (95% CI 0.7-2.3) 
ER+/PR+ – RR= 1.5 (95% CI 0.7-3.1) 
 
T1 - RR=1.5 (95% CI 0.7-3.3) 
T2 – RR=1.5 (95% CI 0.7-3.4) 
T3 – RR=0.8 (95% CI 0.3-1.9) 
 
Luteal phase prolactin: 
All cases – RR=1.0 (95% CI 0.6-1.7) 
Invasive  – RR=0.9 (95% CI 0.5-1.7) 
ER+/PR+ – RR= 0.8 (95% CI 0.4-1.6) 
 
T1 - RR=1.7 (95% CI 0.8-3.7) 
T2 – RR=1.1 (95% CI 0.5-2.4) 
T3 – RR= 0.6 (95% CI 0.2-1.2) 
 
Adjusted for BMI at age 18 yrs, 
weight change from age 18 to 
blood draw, family history of 
breast cancer, age at menarche & 
matching factors  
 
 44 
 
1.4 Summary of Background 
 
Breast density, a reflection of the histologic composition of the breast, is one factor that affects 
mammographic sensitivity and is predictive of breast cancer risk.  Factors that increase breast 
density may compromise the reduction in mortality gained by mammographic screening.  
Understanding these factors may help us improve mammographic screening and reduce breast 
cancer risk. Prolactin, an endogenous hormone that acts as a mitogen and differentiating agent in 
the breast, may be one such factor. The majority of both case-controls and prospective studies 
examining the association between prolactin and breast cancer risk have yielded inconsistent 
results. However, two large prospective study reported a significant positive association between 
prolactin and post-menopausal breast cancer193,194 similar in magnitude to that observed for 
estrogen.26  Prolactin and estrogen act synergistically to exert their mitogenic effects on the 
normal breast. Whereas increased levels of estrogen (for example from HT use) have been linked 
to increased breast density, whether increases in prolactin levels also increase breast density 
remains unknown.   
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2.0 Methods 
 
2.1 Specific Aims 
 
The goal of this study was to correlate serum prolactin levels and breast density in 
postmenopausal women using a cross-sectional study design. In addition, genetic variability in 
both the prolactin gene and prolactin gene receptor were examined to understand how these 
genes may influence mammographic density. To date, no study has examined the association of 
genetic polymorphisms in the prolactin gene nor the prolactin receptor gene and breast density 
among healthy postmenopausal women. The specific aims of this proposal were: 
 
Specific Aim 1: to examine the correlation of serum prolactin levels to breast density. 
 Hypothesis 1.1: among postmenopausal women, higher levels of prolactin are   
 associated with higher breast density.  
 
Specific Aim 2: to determine the association between single nucleotide polymorphisms (SNPs) 
in both the prolactin gene and prolactin gene receptor with serum levels of prolactin and breast 
density in postmenopausal women.  
Hypotheses 2.1: postmenopausal women with polymorphisms in the prolactin gene that 
lower the level of prolactin will lower breast density; and conversely women with 
polymorphisms in the prolactin gene that increase the level of prolactin will have higher 
breast density. 
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2.2 Parent Study Overview 
 
This is an ancillary study to The Mammograms and Masses Study (MAMS), a case-control study 
of estrogen metabolites, mammographic density, and breast cancer risk. 869 cancer-free women 
and 264 recently diagnosed breast cancer cases were recruited into MAMS through the Magee 
Women’s Hospital Mammographic Screening and Diagnostic Imaging Program in the greater 
Pittsburgh, PA area between September 2001 and May 2005. Women who were 18 years of age 
or older, could provide written informed consent and reported no previous personal history of 
cancer, with the exception of non-melanoma skin cancer, were eligible for study enrollment. 
Participants in the MAMS can be classified into three separate groups: (1) recruited from the 
Magee-Women’s Surgical Clinic for an initial evaluation after newly diagnosed primary breast 
cancer; (2) women who were undergoing outpatient needle breast biopsy through the Breast 
Biopsy Service, but who were not subsequently diagnosed with breast cancer (control group 1 – 
benign breast masses); and (3) women receiving screening mammography through Magee-
Women’s Hospital or through Pittsburgh Magee-Womancare Centers (control group 2 – negative 
mammograms). In order to increase recruitment of control group 2, study flyers were attached to 
screened negative mammogram reports mailed to Magee-Womancare Center patients between 
November 2003 and April 2005. 
 
2.3 Ancillary Study Population 
 
Participants were selected for this ancillary study if they met the following eligibility criteria: (1) 
screen negative women (control groups 1 and 2) recruited via study flyers through Magee-
Women’s Hospital or through Pittsburgh Magee-Womancare Centers; (2) 40 years of age or 
older; (3) postmenopausal defined according to the methods described by the Women’s Health 
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Initiative (CITE)198, where age at menopause corresponds to the age at which the participant last 
had any natural menstrual bleeding, had a bilateral oophorectomy, or began using HT. For a 
hysterctomized woman without a bilateral oophorectomy, age at menopause was the earliest age 
at which she began using HT or first had menopausal symptoms. If neither occurred and her age 
at hysterectomy was 50 years or older, then age at menopause as her age at hysterectomy; (4) 
cancer-free; and (5) had a mammogram within three months of blood draw.  
 A total of 1,133 women enrolled in the MAMS Study between September 2001 and May 
2005. Out of these, 264 were women with newly diagnosed breast cancer (case groups), and thus 
excluded from the ancillary study population. From the remaining 869 women (control group), 
222 women were premenopausal and thus excluded from the ancillary study population. From 
the remaining 647 postmenopausal women, 202 women were excluded due a variety of reasons, 
including: 28 non-Caucasian women, 40 women without a blood sample, 47 women without a 
mammogram, 2 women with a previous breast cancer diagnosis, and 85 women had missing 
information on key study variables. Due to the above mentioned exclusions, the resulting sample 
size for this ancillary study consisted of 445 white, cancer-free, healthy, postmenopausal women 
– 104 control group 1 women (benign breast masses) and 341 control group 2 women (negative 
mammograms). 
 
2.4 Protection of Human Subjects 
 
The MAMS was approved by the Magee-Women’s Hospital and the University of Pittsburgh’s 
Institutional Review Boards. All participants provided written informed consent for participation 
and permission to release medical records and mammograms at the time of study entry. All 
participants were provided copies of the signed study consent forms. No study procedures were 
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performed until after written informed consent was given. All data was stored and coded to 
ensure confidentiality. The study coordinator examined all study forms for completeness before 
data entry and removed all identifiers, i.e. name, address, before data entry. Each study 
participant was assigned a study identification number, which was used to label all study 
documents, copies of mammograms, and biological specimens. Identifying information was 
stored separately from the data with the participants study identification number. All hard copies 
were kept in locket file cabinets in a locked office. Information linking the study identifier with 
personal identifiable information was kept under strict security, and only authorized study 
personnel had access to this information. Linking the study ID number to personal identification 
will occur only when strictly necessary. Participants’ records and biological specimens will be 
stored for at least five years subsequent to the completion of the study per University of 
Pittsburgh policy. If a participant withdraws from the study, all study related forms, including 
biological specimens, will be destroyed. 
 
2.5 Questionnaire Data Collection 
 
A standardized self-administered questionnaire was used to obtain exposure information at the 
time of enrollment. Data collected include personal demographic factors (age, race/ethnicity, 
education); medical history; lifestyle factors (exercise, smoking, and alcohol intake); 
reproductive history (age of menarche, parity, age at first full-term birth, duration of 
breastfeeding, age at last natural menstrual bleeding, surgical versus natural menopause, history 
of benign breast disease, and history of breast biopsy); family history of cancer in first-degree 
relatives (mother(s), father(s), sister(s), brother(s)); past HT use and years since HT use. 
Participants were asked to list the type of compounds and dosages for each agent they regularly 
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used. During the baseline clinic visit, the questionnaire was returned to the study coordinator, 
who reviewed it for completion and removed all personal identification information.  
 
2.6 Anthropometric Measurements 
 
The study coordinator obtained anthropometric measurements at the time of study enrollment 
and recorded the information on a standardized form. After the participant removed her shoes 
and heavy clothing, weight was measured at a standing position to the nearest 0.1 kilogram (kg) 
using a standard balance beam. Standing height was measured at full inspiration to the nearest 
0.1 centimeter (cm). All anthropometric measurements were taken twice and were repeated if the 
first two measurements differed by more than 0.5 kg or 0.5 cm. The mean of the measurements 
will be used for all analysis. Body mass index (BMI) was calculated as weight in kilograms 
divided by height in meters squared.  
 
2.7 Mammographic Density Measurements 
 
Mammographic density and parenchymal patterns were determined from mammographic film 
copies and recorded on a standardized form.  The readings were performed by Ms. Martine 
Salane, an expert reader trained by Dr. Wolfe in planimetry.  The reader was blinded to the 
identity and other personal characteristics of the study participants. Mammographic 
measurements were made using a randomly selected craniocaudal view (CC) of one breast from 
each subject. To calculate percent breast density, areas of radiographically dense tissue 
(excluding isolated calcifications, Cooper’s ligaments, biopsy scars, and breast masses) were 
outlined with a china marker. Total breast area and outlined regions were measured using a 
 50 
 
compensating polar planimeter (LASICO, Los Angeles, CA). Percent breast density was 
calculated by dividing the outlined regions of density by the total breast area. Nondense breast 
area was determined by dividing the dense breast area by the total area of the breast. All 
measurements are taken twice to ensure accuracy. The reader also recorded the quality of the 
image (poor ++, poor +, poor, fair, good, excellent). 
In order to assess the reliability of Ms. Salane’s readings, twenty-eight randomly selected 
mammograms (eight from the lowest tertile of percent breast density, and ten each from 
remaining two tertiles of percent breast density) were sent for re-review. The intraclass 
correlation coefficient (ICC) was calculated from an F value that was derived by dividing the 
mean square error terms for the between-patient variance by that of the within-patient variance. 
The intraclass correlation coefficient (ICC)for intra-observer agreement was ρ=0.86 for area of 
density, ρ=0.99 for total area of the breast, and ρ=0.89 for percent breast density. Our ICC for 
percent density is consistent with reports from computer-assisted measurements in the Canadian 
National Breast Screening Study (ICC ρ=0.897 for 150 sets of films),61 the Nurses’ Health Study 
(ICC ρ=0.93),199 and for Ms. Salane’s reproducibility in the Breast Cancer Detection 
Demonstration Project (BCDDP) (ICC ρ=0.915 for 193 sets of films).64 Ms. Salane’s validity 
was evaluated against computer-assisted density measurements showing excellent correlation 
(ρ=0.90).62  
 
2.8 Biological Specimen Collection 
 
At the time of study enrollment, the study coordinator drew 40mL of peripheral non-fasting 
blood from each participant using standardized phlebotomy procedures. Before blood draw, 
information on current medication use (example, aspirin) and time from last meal was recorded 
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for all participants on a standardized form. The 40mL of blood draw consisted of 20mL collected 
without anticoagulant (2 red top tubes), which provides serum as well as clot, and 20mL 
collected into EDTA (purple top tube), which provides plasma and buffy coat.  All samples were 
processed on site at the Magee Women’s Hospital Satellite Clinical Research Center (MWH-S-
CRC) according to well-established protocols. After processing, the samples were aliquotted into 
1mL cryovials in which red blood cell, serum, plasma, and buffy coat were separated. Samples 
are stored in –70°C freezers in the Epidemiology Department at the University of Pittsburgh. 
 
2.9 Prolactin Measurements 
 
Serum prolactin levels were assayed at the laboratory of Dr. Patrick Sluss in the Reproductive 
Endocrine Unit Reference Laboratory at Massachusetts General Hospital. This is the same 
laboratory that is currently used by the Nurses’ Health Study (NHS)193,194,200 Prolactin was 
measured using a fully automated system [AxSYM, Abbott Diagnostics].  The method is a 
microparticle enzyme immunoassay. All reagents for this FDA approved in vitro diagnostic 
method are manufactured and quality controlled by the manufacturer. This method has no 
“hook” effect up to PRL levels of 10,000 ng/mL.  The reportable range of the method is 1-200 
ng/mL. Specimens containing higher than 200 ng/mL are diluted and retested. The assay’s 
detection limit (sensitivity) is 0.6 ng/mL.  Variability within assay duplicates for positive control 
sera are typically less than 5%; between assay variability is less than 8%.  The reported intra-
assay coefficient of variation was 7.6%. 
Plasma samples (250 microliters each) were sent to Dr. Sluss’ laboratory for analysis. 
Technicians were blinded to the source of each sample.  Blinded, duplicate samples were sent for 
5% of subjects to evaluate assay reproducibility.  There was a high level of agreement between 
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the duplicate measures of prolactin. All samples were run in duplicate. Each set of duplicate 
samples were evaluated according to Dr. Sluss’ protocol and the average concentrations for each 
set was reported (ng/mL). The coefficient of variation for duplicate samples must be less than 
10% or the sample was re-assayed.  Research personnel were blinded as to the breast density 
results in order to avoid potential bias in the conducting of the laboratory assays. 
 
2.10 Single Nucleotide Polymorphisms (SNP) Selection 
 
Population genetics research has shown that approximately 90% of the sequence variation among 
individuals is due to common variants.201 In addition, most of those variants arose from single 
historical mutation events and are therefore associated with nearby variants that are present on 
the ancestral chromosome on which the mutation occurred. These two concepts are important for 
the discussion that follows. 
Any two copies of the human genome vary from one another by approximately 0.1% of 
nucleotide sites or one variant per 1,000 bases on average.202,203 The most common type of 
variant, observed at a frequency of ≥1%, is called a single nucleotide polymorphism (SNP). It 
represents a difference between chromosomes in a base present at a particular site in the DNA 
sequence – one individual might have a G (the “G allele”) at the site of interest, whereas another 
individual might have an A (the “A allele”) at that same site. It is estimated that there are 
approximately 10 million sites (1 variant per 300 bases on average) with different alleles. These 
10 million sites are believed to constitute 90% of the variation that is observed in the DNA 
sequence.201 The other 10% of the variation can be attributed to a variety of different variants 
that are rare (occurring at a rate <1%).201 
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Each SNP is the result is a single historical mutational event. The mutation rate is very 
low, in the order of 10-8 per site per generation, when compared to the number of generations 
since the most recent common ancestor of any two humans (in the order of 104 generations). 
Because of this low mutation rate, each new allele is associated with other alleles that were 
present on the particular chromosomal background from which that new allele arose.204 This 
combination of alleles that are observed on either a single chromosome or part of a chromosome 
is referred to as a haplotype. In addition to the above scenario, new haplotypes can also rise as a 
result of additional mutations or due to recombination. Recombination occurs when the maternal 
and paternal chromosomes exchange corresponding segments of DNA, thus resulting in an off-
spring chromosome that is a mosaic of both parental haplotypes.205 
In a haplotype, one observes the coinheritance of different SNP alleles. This 
coinheritance leads to associations between the SNPs, which is a concept known as linkage 
disequilibrium (LD). Because the likelihood of recombination between two alleles increases with 
the distance between them, the associations between alleles decreases with distance. Research 
has indicated that in the human genome there exists highly significant levels of LD, often with 
strong associations to nearby SNPs.206-208 What this means is that in many chromosomal regions, 
there are only a few haplotypes which can account for most of the variation across individuals. 
In order to account for all of the individual variation within either a chromosome or part 
of a chromosome, one would need to genotype all of the SNPs within that region. This can not 
only be very labor intensive, but expensive as well. By utilizing the concept of LD one is able to 
genotype a few, carefully chosen SNPs in the region of interest. These carefully chosen SNPs – 
termed “tagging or tag SNPs” can provide enough information to predict much of the 
information about the remainder of the SNPs found in the region of interest.208,209 It is estimated 
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that approximately 200,000 to 1,000,000 tagging SNPs can account for most of the genetic 
variation represented by the 10 million common SNPs in the human population.  
The importance of using tagging SNPs in research is that it does not require the 
researcher to have prior knowledge of putative functional variants. By using this so-called 
“indirect approach,” a set of sequence variants can serve as genetic markers to detect an 
association between a particular region and the disease in question, whether or not the markers 
themselves have any functional effect. Regions that show an association with the disease can 
then be further tested to find the causative variant(s).204,208,209  
The above observations lead to the development of International HapMap Project in 
2002. The aim of this project is “to determine the common patterns of DNA sequence variation 
in the human genome, by characterizing sequence variants, their frequencies, and correlations 
between them, in DNA samples from populations with ancestry from parts of Africa, Asia, and 
Europe.”204 The International HapMap Project will genotype a total of 270 DNA samples – 90 
samples from a US Utah population with Northern and Western European ancestry (30 trios of 
two parents and an adult child); 90 samples from the Yoruba people in Ibadan, Nigeria (30 trios 
of two parents and an adult child; samples collected in 1980 by the Centre d’Etude du 
Polymorphisme Humain (CEPH)); 45 unrelated samples from Tokyo, Japan; and 45 unrelated 
samples from the Han Chinese in Beijing, China. All of the information collected will be 
available free of charge on the world wide web at http://www.hapmap.org.204 
HapMap and its accompanying program, Haploview, were used to identify tagging SNPs 
for both the prolactin gene and the prolactin receptor gene.  
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2.10.1 Prolactin SNP Selection  
 
Using the HapMap Data Rel 19/phase II Oct05, on NCBI 34 assembly, dbSNP b124 dataset, the 
code for prolactin (PRL) was inputted into the landmark or region section. The SNP genotype 
data for the CEU (US Utah population with Northern and Western European ancestry) 
population extending to 40 kbp was exported into Haploview. For PRL, a total of 16 SNPs 
account for the total variability within the PRL gene.  Using a minor allele frequency (MAF) of 
10%, the Tagger program was run using the 2-3-marker haplotype selection feature. The 2-3-
marker haplotype selection allows the Tagger algorithm to test all possible two- and three-way 
SNP combinations, to see if they give you additional information that each of the individual 
SNPs by themselves. The program selected seven tagging SNPs – rs1205955, rs2744119, 
rs1205961, rs12210179, rs849877, rs1341239, and rs6456483. These seven tagging SNPs result 
in the formation of one LD block (Figure 5 and Figure 6 ), capture 100% of alleles with an r2 
>0.8 and capture 7 of 7 alleles (SNPs) with a mean r2 of 1.0. 
 
2.10.2 Prolactin Receptor SNP Selection  
 
Using the HapMap Data Rel 19/phase II Oct05, on NCBI 34 assembly, dbSNP b124 dataset, the 
code for the prolactin receptor (PRLR) was inputted into the landmark or region section. The 
SNP genotype data for the CEU (US Utah population with Northern and Western European 
ancestry) population extending to 200 kbp was exported into Haploview. For the PRLR, a total 
of 86 SNPs account for the total variability within the PRLR gene.  Using a minor allele 
frequency (MAF) of 10%, the Tagger program was run using the 2-3-marker haplotype selection 
feature. The program selected 15 tagging SNPs – rs1609500, rs4703505, rs401694, rs7734558, 
rs7727306, rs6866465, rs6897600, rs1587608, rs1587059, rs7720677, rs685193, rs1587607, 
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rs249522, rs4235652, rs7705216. These fifteen tagging SNPs result in the formation of six LD 
blocks (Figure 7 and Figure 8), capture 100% of alleles with an r2 >0.8 and capture 31 of 31 
alleles (SNPs) with a MAF ≥10% with a mean r2 of 0.956. 
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Figure 5:  Linkage disequilibrium block structure of the prolactin gene  
Notes:  Linkage disequilibrium (LD) block structure of the prolactin (PRL) gene based on a minor allele frequency of 10%. 
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Figure 6:  Haplotype of the prolactin gene based on a minor allele frequency of 10%. 
Notes: The numbers on top of each block correspond to each individual SNP number: 
   #1 – rs6456483   #9 – rs849877 
   #3 – rs2744119   #11 – rs12210179 
   #4 – rs1205961   #14 – rs1341239 
   #7 – rs1205955    
 
 The pattern of, for example, CATC, represents a haplotype. As can be seen in block 1, approximately 63% of genotypes will 
have either the CATC or GATT haplotype – here the difference being which allele is present in SNP #1 and #4. The numbers between 
each block can be thought of as a correlation between blocks. For example, block 2 captures 53% of the allelic variability in block 1. 
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Figure 7:  Linkage disequilibrium block structure of the prolactin receptor gene 
Notes:  Linkage disequilibrium (LD) block structure of the prolactin receptor (PRLR) gene based on a minor allele frequency of 10%. 
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Figure 8:  Haplotype of the prolactin receptor (PRLR) gene based on a minor allele frequency of 10%. 
Notes:  The numbers on top of each block correspond to each individual SNP number: 
   #2 - rs1587059   #63 – rs4235652 
   #6 – rs249522    #65 – rs1609500 (not shown) 
   #7 – rs401694    #66 – rs6866465 
   #30 – rs7734558   #78 – rs1587608 
   #53 – rs4703505 (not shown)  #83 – rs7727306 
   #54 – rs6895193 (not shown)  #85 – rs7720677 
   #58 – rs7705216 (not shown)  #86 – rs6897600 
   #59 – rs1587607   
 
 The pattern of, for example, CAGCTA, represents a haplotype. As can be seen in block 1, approximately 63% of genotypes 
will have either the CAGCTA or the GAGCTA haplotype – here the difference being which allele is present in SNP #2. The numbers 
between each block can be thought of as a correlation between blocks. For example, block 2 captures 74% of the allelic variability in 
block 1. 
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2.11 SNP Genotyping 
The SNPs were genotyped in the Molecular Genetics Laboratory in the Department of Human 
Genetics at the Graduate School of Public Health, University of Pittsburgh ran by Dr. Robert 
Ferrell.  High molecular weight DNA was isolated from banked buffy coat specimens using a 
commercial protocol (PureGene DNA Isolation Kit, Gentra Systems, Inc. Minneapolis, MN). 
SNPs were genotyped  by the 5'-nuclease (TaqMan) assay210 using the ABI 7900HT sequence 
detector. Assay development used the Assay-by-Design and Assay-on-Demand services of 
Applied Biosystems, Inc., and assays were carried out in a 384 well format. Each genotyping run 
included multiple controls of known genotype, established by direct sequencing, and no template 
controls. Genotype assignments were reviewed by Dr. Ferrell, and any disagreements resolved 
by consensus or retyping. Samples were only labeled with an ID number and study investigators 
were blind to serum prolactin levels and breast density results to avoid potential bias in the 
conducting of the laboratory assays. 
 
2.12 Data Quality Management 
 
To prevent data errors a variety of procedures were implemented. All anthropometric 
measurements were taken twice and standardized data collection instruments were used. 
Completed questionnaires were checked and edited by both the study coordinator and a research 
assistant before data entry. If any missing information was found, several attempts were made to 
contact the participant. In addition, double entry verification was used to enter all data and to 
ensure data reliability. The data manager routinely checked for ID validation, unusual codes and 
extreme values to further reduce the likelihood of data-entry errors. Each data file was 
thoroughly cleaned before being merged with the master data set.  
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2.13 Statistical Analysis 
 
2.13.1 Specific Aim 1: Correlation of Prolactin with Breast Density  
 
Because prolactin (PRL) levels were not normally distributed, non-parametric methods were 
used to test the correlation between breast density and serum PRL levels. Breast density and 
serum PRL levels were analyzed using Spearman’s correlation. To test for possible confounders 
that have been shown to affect breast density, serum prolactin levels and breast density were 
regressed on each potential confounder.  For each potential confounder, two linear regression 
models were run – the first regressed the potential confounder on prolactin levels, and the second 
regressed the potential confounder on breast density levels.  Spearman’s correlation was then 
utilized to examine the correlation between the residuals obtained from each of the two 
regression models. This same procedure was utilized to examine all potential confounders – age, 
weight, BMI, age at menarche, ever pregnant, age at first full-term pregnancy, number of live 
births, ever breast fed, number of children breast fed, age at menopause, surgical menopause, 
current hormone therapy user, history of breast cysts, family history of breast cancer, current 
smoker, drank alcohol in the past twelve months, and walks for exercise, individually. Those 
confounders whose residuals were significant (p-value 0.05) based on the results from the 
Spearman’s correlation coefficient (ever pregnant and ever breast fed) were then combined and 
analyzed in the same manner as described above. 
2.13.2 Specific Aim 2: Association of Prolactin and Prolactin Receptor Polymorphisms 
with Prolactin Levels and Breast Density 
 
For each SNP, allele frequencies were analyzed and each genotypic distribution was tested for 
Hardy-Weinberg equilibrium using a chi-square goodness of fit statistic.   
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Using freely available software found online and specifically created for genetic analysis, 
such as R, the linkage disequilibrium of each SNP within each gene will be tested to determine 
the efficacy of haplotype-based analyses.   If the results are positive, haplotype analyses will be 
conducted using existing techniques.  Multivariable linear models for each SNP/haplotype with 
either breast density or serum PRL level as the outcome variable will be utilized, controlling for 
potential confounders. If either breast density or PRL levels are not normally distributed, they 
will be appropriately transformed. In order to deal with the problem of multiple corrections, 
permutation testing, in addition to other methods, may be utilized. 
 
2.14 Power/Sample Size Calculations 
 
All power calculations were done using PASS 6.0. 
 
2.14.1 Specific Aim 1: Correlation of Prolactin with Breast Density 
 
As can be seen from Table 4, in order to detect a significant correlation of 0.15 between serum 
prolactin levels and mammographic density, 462 subjects will be needed to obtain 90% power. If 
the observed correlation increases, the sample size would then decrease.  Anticipating that up to 
10% of the samples will be unsuable due to factors unrelated to either breast density or prolactin 
levels, increasing the sample size to 500 will be more than adequate to detect a significant 
correlation between PRL levels and breast  density of 15% or higher.  
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Table 4:  Sample Size and Power Calculations for Specific Aim 1. 
Power N Alpha Ho Ha 
0.90002 462 0.05 0.00 0.15 
0.80048 346 0.05 0.00 0.15 
0.95045 319 0.05 0.00 0.20 
0.95040 138 0.05 0.00 0.30 
0.95132 75 0.05 0.00 0.40 
0.95351 46 0.05 0.00 0.50 
0.95548 30 0.05 0.00 0.60 
 
Ho: The is no correlation between PRL levels and breast density 
Ha: There is a correlation between PRL levels and breast density 
 
2.14.2 Specific Aim 2: Association of Prolactin and Prolactin Receptor Polymorphisms 
with Prolactin Levels and Breast Density  
 
To determine the sample size for the prolactin gene SNP analysis, a Bonferroni correction for 
multiple comparisons will be utilized. For the PRL gene, seven SNPs will be analyzed, 
corresponding to a comparison-wise type I error of 0.007 (0.05/7). To detect an effect size of 
0.20 with a type I error of 0.007 and 80% power, a sample size of 308 participants is required 
(Table 5).  
 
Table 5:  Sample Size and Power Calculations for Specific Aim 2 – PRL Gene. 
N Alpha Ho Ha 
308 0.007 0.00 0.20 
134 0.007 0.00 0.30 
73 0.007 0.00 0.40 
 
 Ho: The is no correlation between PRL SNPs and PRL levels and breast density   
 Ha: There is a correlation between PRL SNPs and PRL levels and breast density  
 
 
For the PRLR gene, 15 SNPs will be analyzed, corresponding to a comparison-wise type I error 
of 0.0033 (0.05/15). To detect an effect size of 0.20 with a type I error of 0.0033 and 80% power, 
a sample size of 351 participants is required (Table 6).  
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Table 6:  Sample Size and Power Calculations for Specific Aim 2 – PRLR Gene. 
N Alpha Ho Ha 
351 0.0033 0.00 0.20 
152 0.0033 0.00 0.30 
83 0.0033 0.00 0.40 
 
Ho: The is no correlation between PRLR SNPs and PRL levels and breast density   
Ha: There is a correlation between PRLR SNPs and PRL levels and breast density  
  
 66 
 
3.0 Results 
 
3.1 Descriptive Analysis 
 
In the overall sample of white, postmenopausal, cancer-free healthy women (Table 7), we 
observed a mean serum prolactin level of 10.62 ± 6.89 ng/mL (standard deviation), a mean breast 
dense area of 43.53 ± 28.30 cm2, and a mean percent breast density of 31.41 ± 19.87.   The 
majority of women were ever pregnant (84.04%), with most giving birth to their first child in 
their 20s (44.13% between 20-24 years of age and 27.93% between 25-29 years of age), having 
at least 2 children (36.03% had 2 live births and 46.93% had 3 live births), and breast feeding at 
some point (41.94% of those who gave birth to a live child).  The women in our sample 
experienced menopause before the age of 50 years (mean age at menopause 48.19 ± 5.18 years), 
30% had a hysterectomy, and most (43.24%) were former hormone therapy users.  
Approximately 14% had a family history of breast cancer in first-degree relatives and 7% had a 
history of benign breast cysts.   
Because our sample population consisted of two groups of women – control group 1 
(benign breast masses) and control group 2 (negative mammograms) – comparison analysis were 
run on the descriptive variables. Women in control group 2 started their menses at a younger age 
(31.67% vs. 19.23% at 12 years of age), and were more likely to be former hormone therapy 
users (48.68% vs. 25.24%) when compared with control group 1 women.  In contrast, group 1 
women were more likely to be younger (mean age of 57.44 ± 7.41 years vs. 62.07 ± 8.27 years), 
more likely to be current smokers (32.65% vs. 11.11%), had a greater proportion of breast dense 
area (50.57 ± 31.57 cm2 vs. 41.38 ± 26.91 cm2), and had greater breast density (36.44 ± 19.86% 
vs. 29.87 ± 19.65%) when compared with group 1 women. 
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Table 7: Descriptive characteristics of white, postmenopausal, cancer-free healthy women 
in the Mammograms and Masses Study (MAMS) 
Descriptive Variable Overall  Group 1 Group 2 p-value* 
 n = 445  n = 104 n=341  
      
Prolactin ± SD, ng/mL 10.62 ± 6.89  10.94 ± 5.87 10.52 ± 7.18 0.585 
Proportion of dense breast area, cm2 43.53 ± 28.30  50.57 ± 31.57 41.38 ± 26.91 0.004 
Percent breast density, % 31.41 ± 19.87  36.44 ± 19.86 29.87 ± 19.65 0.003 
Age ± SD, years 60.99 ± 8.30  57.44 ± 7.41 62.07 ± 8.27 <0.001 
Weight ± SD, kg 73.70 ± 16.09  71.94 ± 15.30 74.23 ± 16.31 0.207 
BMI ± SD, kg/m2 27.99 ± 5.89  27.36 ± 5.38 28.18 ± 6.03 0.218 
Age at Menarche, %      
   <12 years 17.30  16.35 17.60 0.034 
   12 years 28.76  19.23 31.67  
   13 years 33.03  43.27 29.91  
   ≥14 years 20.90  21.25 20.82  
Ever Pregnant, % 84.04  86.54 83.28 0.428 
Age at 1st full-term pregnancy, %      
   <20 years 11.17  14.29 10.22 0.874 
   20-24 years 44.13  44.05 44.16  
   25-29 years 27.93  26.19 28.47  
   30-34 years 12.01  10.71 12.41  
   ≥35 years 4.75  4.76 4.74  
Number of live births§, %      
   1 17.04  20.00 16.12 0.647 
   2 36.03  32.94 37.00  
   ≥3 46.93  47.06 46.89  
Ever breast fed§, % 41.94  35.58 43.94 0.132 
Number of children breast fed‡, %      
   1 40.66  48.65 38.62 0.513 
   2 30.22  24.32 31.72  
   ≥3 29.12  27.03 29.66  
Age at menopause ± SD, years 48.19 ± 5.18  47.26 ± 5.19 48.48 ± 5.15 0.039 
Surgical menopause, % 30.56  36.54 28.74 0.131 
Hormone therapy (HT), %      
   Never HT user 32.88  16.50 37.83 <0.001 
   Former HT user 43.24  25.24 48.68  
   Current HT user 23.87  58.25 13.49  
History of breast cysts, % 6.97  54.84 36.84 0.135 
Family history of breast cancer, % 14.38  11.65 15.34 0.351 
Current smoker, % 7.19  32.65 11.11 <0.001 
Drank alcohol in past 12 months, % 25.39  66.67 60.96 0.527 
Walks for exercise, % 60.22  56.44 61.88 0.326 
 
§ Among parous women; ‡ Among parous women who breast fed 
 
* Level of significance (p-value) determined from either the Chi-square test for categorical variables or the t-test for 
continuous variables 
 
Abbreviations used: Group 1 – women with benign breast masses; Group 2 – women with negative mammograms; 
SD – standard deviation 
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Although a significant difference was observed for current smokers, there was no 
difference in mean prolactin levels between women in control group 1 and 2 (10.81 ± 6.19 
ng/mL vs. 10.91 ± 7.66 ng/mL). Additionally, no differences in mean prolactin levels were 
observed for either former hormone therapy users (10.15 ± 5.97 ng/mL for control group 1 
women vs. 10.87 ± 5.18 ng/mL for control group 2 women) or current (within the past three 
months prior to study enrollment and blood draw) hormone therapy users (10.00 ± 4.70 ng/mL 
for control group 1 women ng/mL vs. 11.34 ± 6.75 ng/mL for control group 2 women).   
 
3.2 Analysis of Serum Prolactin Level Predictors 
 
Neither serum prolactin levels nor prolactin residuals were normally distributed (Figure 9). After 
an analysis of various transformations, it was determined that the log transformation would be 
the most appropriate to bring prolactin values closer to normality (Figure 9). 
In order to determine potential predictors for prolactin serum levels, linear regression 
analysis was performed and the residuals were analyzed.  Two separate models were constructed.  
The first utilized the variables found to be significant at the 0.10 level in the bi-variate analysis 
(ever pregnant, number of live births, ever breast feeding, and number of children breast fed) as 
potential predictors of serum prolactin levels.  The second model utilized the variables listed in 
the literature (age, age at first full-term pregnancy, age at menarche, age at menopause, number 
of live births, ever breast feeding, family history of breast cancer in first-degree relatives, history 
of benign breast cysts, hormone therapy use and body mass index) as potential predictors of 
serum prolactin levels.   
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(a) Serum prolactin levels         (b) Prolactin residuals 
 
 
          
 
    (c) Potential prolactin transformations      (d) Potential prolactin transformations 
 
 
 
 
(e) Log transformation of prolactin 
 
Figure 9: Normality analysis of serum prolactin levels 
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 Both models yielded the same exact results – the only variable found to be a statistically 
significant predictor of serum prolactin levels (log transformed) was ever breast feeding.  
Women who breast fed were more likely to have a decreased level of log transformed prolactin 
(0.884, 95% CI 0.812-0.962, p-value 0.004). A histogram and scatterplot of the residuals from 
this model can be found in Figure 10. 
 
 
     
   (a) Scatterplot of residuals    (b) Histogram of residuals 
 
Figure 10: Analysis of the residuals from the final linear regression model of predictors of 
serum prolactin levels. 
 
3.3 Correlation Analysis of Prolactin (PRL) and Percent Breast Density 
 
A spearman correlation coefficient of 0.1167 (p-value 0.018) was obtained for the correlation 
between prolactin and percent breast density. In order to determine if any other variables could 
impact this correlation, several analyses were run between prolactin and each of the descriptive 
variables (Table 8). The only significant correlations observed were between prolactin and ever 
being pregnant (p-value 0.005) and between prolactin and ever breast feeding (p-value 0.007).  
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Table 8: Correlation between prolactin and descriptive variables among white, 
postmenopausal, cancer-free healthy women in the Mammograms and Masses Study 
(MAMS). 
Variable Correlation p-value 
% density 0.12 0.018 
Age -0.09 0.073 
Weight -0.07 0.141 
BMI -0.06 0.249 
Age at Menarche   
   12 years 0.00 0.934 
   13 years 0.03 0.516 
   ≥14 years -0.05 0.309 
Ever Pregnant -0.16 0.005 
Age at 1st full-term pregnancy   
   20-24 years 0.04 0.507 
   25-29 years -0.00 0.969 
   30-34 years 0.01 0.825 
   ≥35 years -0.00 0.948 
Number of live births   
   1 0.05 0.341 
   2 -0.09 0.064 
   ≥3 -0.06 0.184 
Ever breast fed -0.13 0.007 
Number of children breast fed   
   1 -0.07 0.123 
   2 -0.09 0.059 
   ≥3 -0.03 0.530 
Age at menopause 0.03 0.543 
Surgical menopause 0.06 0.217 
Current hormone therapy user 0.03 0.587 
History of breast cysts -0.06 0.215 
Family history of breast cancer -0.03 0.575 
Current smoker -0.09 0.222 
Drank alcohol in past 12 mths 0.09 0.251 
Walks for exercise 0.08 0.109 
Aspirin in last 48 hrs before 
blood draw 
-0.09 0.077 
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In order to determine if ever pregnant and/or ever breast feeding could confound the 
observed correlation between prolactin and percent breast density, separate spearman correlation 
analyses were run to examine the impact of the above mentioned variables.  After adjusting for 
ever being pregnant and ever breast feeding (Table 9), the observed correlation between 
prolactin and percent breast density increased slightly (spearman correlation coefficient of 
0.1197; p-value 0.013) and remained statistically significant.  
 
Table 9: Spearman correlation matrix between prolactin, percent breast density, ever 
pregnant, and ever having breast fed in white, postmenopausal, cancer-free, healthy 
women in the Mammograms and Masses Study (MAMS). 
 Prolactin % breast 
density 
Ever pregnant Ever having 
breast fed 
Prolactin 1.0000    
     
% breast density 0.1197 1.0000   
 p-value 0.013    
     
Ever pregnant -0.1515 -0.1401 1.0000  
 p-value <0.001 p-value 0.004   
     
Ever having 
breast fed 
-0.1295 0.0823 0.3404 1.0000 
p-value 0.007 p-value 0.087 p-value <0.001  
 
 
 Separate spearman correlation analyses were performed to examine the potential 
correlation between percent breast density and each of the descriptive variables. Aside from ever 
being pregnant (spearman correlation coefficient of -0.1259; p-value 0.000), none of the other 
descriptive variables were found to be statistically significant (data not shown).  Additionally, 
the correlation between prolactin and dense breast area (spearman correlation coefficient of 
0.0749; p-value 0.115) was not statistically significant. 
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3.4 Analysis of Prolactin (PRL) Single Nucleotide Polymorphisms  
 
Seven single nucleotide polymorphisms (SNPs) were identified as tagging SNPs.  Out of these, 
rs1205955 could not be genotyped and was dropped from the analysis. All of the remaining six 
SNPs (rs6456483, rs2744119, rs1205961, rs849877, rs12210179, and rs1341239) were in Hardy-
Weinberg equilibrium (Table 10). No differences in genotype frequency were observed between 
control group 1 (benign breast masses) women and control group 2 (negative mammograms) 
women (Table 10).  No statistically significant differences were found in regards to either serum 
prolactin levels, percent breast density, or proportion of dense breast area among the various 
SNPs (Table 11).  
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Table 10: Prolactin single nucleotide polymorphism (PRL SNP) genotype frequency among 
white, postmenopausal, cancer-free healthy women in the Mammograms and Masses Study 
(MAMS). 
PRL SNP Genotype Overall n (%) 
HapMap 
Distribution§ (%) 
HWE 
p-value‡ 
Group 1 
n (%) 
Group 2 
n (%) p-value* 
rs6456483 CC 157 (35.9) 32.8 0.536 45 (44.6) 112 (33.3) 0.072 
 CG 215 (49.2) 50.0  40 (39.6) 175 (52.1)  
 GG 65 (14.9) 17.2  16 (15.8) 49 (14.6)  
        
rs2744119 AA 347 (80.5) 75.0 0.503 80 (81.6) 267 (80.2) 0.912 
 AG 78 (18.1) 21.7  17 (17.3) 61 (18.3)  
 GG 6 (1.4) 3.3  1 (1.1) 5 (1.5)  
        
rs1205961 GG 159 (36.6) 45.0 0.963 34 (34.3) 125 (37.3) 0.704 
 AG 207 (47.7) 40.0  47 (47.5) 160 (47.8)  
 AA 68 (15.7) 15.0  18 (18.2) 50 (14.9)  
        
rs849877 CC 58 (13.6) 15.5 0.330 9 (9.3) 49 (14.9) 0.246 
 TC 211 (49.5) 43.1  54 (55.7) 157 (47.7)  
 TT 157 (36.9) 41.4  34 (35.1) 123 (37.4)  
        
rs12210179 TT 220 (50.5) 52.5 0.145 49 (49.0) 171 (50.9) 0.208 
 TC 188 (43.1) 42.4  48 (48.0) 140 (41.7)  
 CC 28 (6.4) 5.1  3 (3.0) 25 (7.4)  
        
rs1341239 CC 153 (35.7) 38.3 0.527 35 (36.1) 118 (35.6) 0.319 
 AC 211 (49.3) 50.0  52 (53.6) 159 (48.0)  
 AA 64 (15.0) 11.7  10 (10.3) 54 (16.3)  
 
§ Single nucleotide polymorphism (SNP) distribution for whites with Northern and European ancestry 
 
‡ HWE – Hardy Weinberg equilibrium chi-square goodness of fit statistic 
 
* p-value determined by a chi-square 
 
Abbreviations used: Group 1 – women with benign breast masses; Group 2 – women with negative mammograms  
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Table 11: Association between prolactin single nucleotide polymorphisms (PRL SNP) and serum prolactin levels, percent 
breast density, and proportion of dense breast area among white, postmenopausal, cancer-free healthy women in the 
Mammograms and Masses Study (MAMS). 
PRL SNP Genotype PRL, ng/mL (mean ± SD) p-value§ 
Percent Breast 
Density, % 
(mean ± SD) 
p-value§ 
Proportion of Dense 
Breast Area, cm2 
(mean ± SD) 
p-value§ 
rs6456483 CC 10.31 ± 4.97 0.684 31.19 ± 20.50 0.176 45.15 ± 30.22 0.660 
 CG 10.87 ± 7.15  32.50 ± 19.41  41.48 ± 24.67  
 GG 9.57 ± 3.96  27.43 ± 18.74  41.90 ± 27.00  
        
rs2744119 AA 10.46 ± 6.28 0.556 31.58 ± 19.51 0.120 42.46 ± 26.17 0.196 
 AG 10.55 ± 5.23  29.59 ± 20.98  45.57 ± 34.79  
 GG 10.66 ± 2.11  43.24 ± 14.09  58.03 ± 18.67  
        
rs1205961 GG 9.83 ± 4.24 0.256 30.74 ± 18.70 0.321 42.70 ± 27.87 0.468 
 AG 10.49 ± 6.20  32.82 ± 21.29  44.67 ± 28.67  
 AA 11.80 ± 8.54  27.68 ± 17.73  40.36 ±27.03  
        
rs849877 CC 10.19 ± 4.14 0.898 29.50 ± 19.30 0.346 40.46 ± 24.35 0.790 
 TC 10.73 ± 6.57  30.98 ± 20.11  43.51 ± 27.81  
 TT 10.41 ± 6.01  32.92 ± 19.53  44.27 ± 28.98  
        
rs12210179 TT 10.19 ± 5.77 0.270 27.42 ± 18.09 0.352 44.39 ± 28.06 0.525 
 TC 10.78 ± 6.59  30.66 ± 20.51  42.13 ± 27.98  
 CC 10.64 ± 3.80  27.42 ± 18.09  38.83 ± 24.14  
        
rs1341239 CC 10.36 ± 6.09 0.659 32.84 ± 19.41 0.389 43.98 ± 27.20 0.869 
 AC 10.65 ± 6.47  31.18 ± 20.12  43.42 ± 28.84  
 AA 10.53 ± 6.08  29.67 ± 19.54  42.24 ± 26.14  
 
§ Krustal-Wallis test for siginificance  
 
Abbreviations used: SD – standard deviation 
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3.5 Analysis of Prolactin Receptor (PRLR) Single Nucleotide Polymorphisms  
 
Fifteen single nucleotide polymorphisms (SNPs) were identified as tagging SNPs.  Out of these, 
rs1587607 could not be genotyped and was dropped from the analysis. All of the remaining 
thirteen SNPs (rs1587059, rs249522, rs7737558, rs4703505, rs6895913, rs7705216, rs4235652, 
rs1609500, rs6866465, rs1587608, rs7727306, rs7720677, and rs6897600) were in Hardy-
Weinberg equilibrium (Table 12).  SNP rs401694 was not in Hardy-Weinberg equilibrium, 
mainly because the heterozygous genotype was not observed for this SNP, thus representing a 
genotyping error and resulting in it being dropped from the analysis. Additionally, SNP 
rs6866465 was also not in Hardy-Weinberg equilibrium, mainly because the homozygous minor 
allele genotype was not observed for this SNP, thus representing an additional genotyping error 
and resulting in it being dropped from the analysis. In regards to SNP rs4703505, women with 
negative mammograms (control group 2) were more likely to have the GG homozygous 
genotype (54.6% vs. 49.5%) than the benign women (control group 1), who were more likely to 
have the AA homozygous genotype (14.1% vs. 4.5%).  No other differences in genotype 
frequency were observed between control groups (Table 12).  No statistically significant 
differences were found in regards to either serum prolactin levels, percent breast density, or 
proportion of dense breast area among the various prolactin receptor SNPs (Table 13).  
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Table 12: Prolactin Receptor (PRLR) SNPs genotype frequency among white, 
postmenopausal, cancer-free healthy women in the Mammograms and Masses Study 
(MAMS). 
 
PRLR SNP Genotype Overall n (%) 
HapMap 
Distribution§ 
(%) 
HWE 
p-value‡ 
Group 1 
n (%) 
Group 2 
n (%) p-value* 
rs1587059 CC 179 (41.4) 48.3 0.803 39 (39.8) 140 (41.9) 0.432 
 CG 200 (46.3) 43.3  50 (51.0) 150 (44.9)  
 GG 53 (12.3) 8.3  9 (9.2) 44 (13.2)  
        
rs249522 CC 331 (76.8) 73.3 0.358 76 (76.0) 255 (77.0) 0.767 
 TC 91 (21.1) 25.0  21 (21.0) 70 (21.1)  
 TT 9 (2.1) 1.7  3 (3.0) 6 (1.8)  
        
rs401694 CC 395 (97.1) 63.3 0.000 94 (96.9) 301 (97.1) 0.923 
 CT  35.0     
 TT 12 (2.9) 1.7  3 (3.1) 9 (2.9)  
        
rs7734558 AA 130 (29.7) 31.7 0.516 34 (34.0) 96 (28.4) 0.559 
 AG 211 (48.2) 55.0  45 (45.0) 166 (49.1)  
 GG 97 (22.1) 13.3  21 (21.0) 76 (22.5)  
        
rs4703505 GG 233 (53.4) 43.3 0.648 49 (49.5) 184 (54.6) 0.003 
 AG 174 (39.9) 51.7  36 (36.4) 138 (40.9)  
 AA 29 (6.7) 0.05  14 (14.1) 15 (4.5)  
        
rs6895913 GG 190 (43.8) Not reported 0.598 51 (51.0) 139 (41.6) 0.251 
 AG 198 (45.6) Not reported  40 (40.0) 158 (47.3)  
 AA 46 (10.6) Not reported  9 (9.0) 37 (11.1)  
        
rs7705216 CC 332 (75.6) 73.3 0.588 72 (72.0) 260 (76.7) 0.574 
 CG 101 (23.0) 0.0  26 (26.0) 75 (22.1)  
 GG 6 (1.4) 26.7  2 (2.0) 4 (1.2)  
        
rs4235652 TT 311 (73.0) 67.8 0.199 71 (72.4) 240 (73.2) 0.795 
 TC 102 (23.9) 28.8  23 (23.5) 79 (24.1)  
 CC 13 (3.1) 3.4  4 (4.1) 9 (2.7)  
        
rs1609500 AA 196 (47.6) 41.7 0.497 45 (45.9) 151 (48.1) 0.045 
 AC 172 (41.7) 46.7  36 (36.7) 136 (43.3)  
 CC 44 (10.7) 11.7  17 (17.3) 27 (8.6)  
        
rs6866465 TT 350 (83.9) 84.7 0.074 85 (87.6) 265 (82.8) 0.258 
 CT 67 (16.1) 13.6  12 (12.4) 55 (17.2)  
 CC 0 1.7     
        
rs1587608 AA 241 (55.4) 51.7 0.634 52 (52.0) 189 (56.4) 0.222 
 AT 163 (37.5) 45.0  37 (37.0) 126 (37.6)  
 TT 31 (7.1) 3.3  11 (11.0) 20 (6.0)  
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Table 12 (Continued) 
 
PRLR SNP Genotype Overall n (%) 
HapMap 
Distribution§ 
(%) 
HWE 
p-value‡ 
Group 1 
n (%) 
Group 2 
n (%) p-value* 
rs7727306 CC 144 (33.0) 36.7 0.848 32 (32.0) 112 (33.2) 0.944 
 CT 212 (48.5) 41.7  50 (50.0) 162 (48.1)  
 TT 81 (18.5) 21.7  18 (18.0) 63 (18.7)  
        
rs7720677 CC 283 (64.6) 63.3 0.480 60 (59.4) 223 (66.2) 0.242 
 CT 141 (32.2) 33.3  39 (38.6) 102 (30.3)  
 TT 14 (3.2) 3.3  2 (2.0) 12 (3.6)  
        
rs6897600 AA 195 (44.8) 45.0 0.608 49 (48.5) 146 (43.7) 0.422 
 AC 196 (45.1) 46.7  45 (44.6) 151 (45.2)  
 CC 44 (10.1) 8.3  7 (6.9) 37 (11.1)  
 
§ Single nucleotide polymorphism (SNP) distribution for whites with Northern and European ancestry 
 
‡ HWE – Hardy Weinberg equilibrium chi-square goodness of fit statistic 
 
* p-value determined by a chi-square 
 
Abbreviations used: SD – standard deviation 
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Table 13: Association between prolactin receptor (PRLR) SNPs and serum prolactin levels, percent breast density, and 
proportion of dense breast area among white, postmenopausal, cancer-free healthy women in the Mammograms and Masses 
Study (MAMS). 
PRLR SNP Genotype PRL, ng/mL (mean ± SD) p-value§ 
Percent Breast 
Density, % 
(mean ± SD) 
p-value§ 
Proportion of Dense 
Breast Area, cm2 
(mean ± SD) 
p-value§ 
rs1587059 CC 9.54 ± 3.65 0.354 32.07 ± 20.66 0.601 43.16 ± 28.17 0.623 
 CG 11.36 ± 7.68  30.98 ± 18.99  43.94 ± 27.41  
 GG 10.40 ± 5.09  29.32 ± 20.95  41.38 ± 31.03  
        
rs249522 CC 10.48 ± 6.49 0.494 31.49 ± 20.36 0.819 43.65 ± 28.36 0.963 
 TC 10.40 ± 4.50  30.95 ± 18.21  42.53 ± 28.04  
 TT 10.34 ± 2.94  28.17 ± 22.04  43.20 ± 26.36  
        
rs7734558 AA 9.86 ± 6.32 0.070 32.98 ± 20.49 0.208 46.54 ± 28.16 0.182 
 AG 10.76 ± 6.40  31.49 ± 19.78  41.95 ± 27.96  
 GG 10.77 ± 4.60  28.25 ± 18.87  41.36 ± 28.11  
        
rs4703505 GG 10.46 ± 6.67 0.148 30.53 ± 19.95 0.487 42.92 ± 28.07 0.482 
 AG 10.24 ± 4.89  31.75 ± 19.53  42.34 ± 27.05  
 AA 12.18 ± 6.66  34.73 ± 20.62  48.96 ± 30.20  
        
rs6895913 GG 10.53 ± 6.45 0.902 32.26 ± 19.65 0.461 44.77 ± 28.15 0.402 
 AG 10.41 ± 5.87  30.90 ± 19.69  42.57 ± 26.54  
 AA 10.59 ± 5.01  28.02 ± 17.77  37.78 ± 22.84  
        
rs7705216 CC 10.27 ± 5.99 0.080 31.21 ± 19.85 0.575 42.91 ± 26.93 0.757 
 CG 11.15 ± 6.22  31.91 ± 19.14  43.86 ± 29.73  
 GG 11.71 ± 2.78  25.22 ± 26.73  38.60 ± 39.98  
        
rs4235652 TT 10.69 ± 6.68 0.183 30.97 ± 19.49 0.200 41.97 ± 26.57 0.083 
 TC 10.10 ± 4.10  35.08 ± 21.11  49.20 ± 31.96  
 CC 7.76 ± 1.85  27.13 ±16.74  39.61 ± 28.33  
 
 80 
 
Table 13 (Continued) 
 
PRLR SNP Genotype PRL, ng/mL (mean ± SD) p-value§ 
Percent Breast 
Density, % 
(mean ± SD) 
p-value§ 
Proportion of Dense 
Breast Area, cm2 
(mean ± SD) 
p-value§ 
rs1609500 AA 10.68 ± 7.05 0.555 30.78 ± 20.08 0.540 48.65 ± 35.02 0.558 
 AC 10.31 ± 5.01  32.83 ± 19.25  42.43 ± 25.34  
 CC 11.10 ± 5.74  31.47 ± 20.26  48.65 ± 35.02  
        
rs1587608 AA 10.53 ± 6.65 0.655 30.60 ± 19.96 0.448 41.75 ± 25.56 0.618 
 AT 10.35 ± 5.31  32.79 ± 19.53  44.92 ± 29.56  
 TT 10.29 ± 3.79  31.92 ± 21.35  49.04 ± 38.39  
        
rs7727306 CC 10.35 ± 4.34 0.662 30.88 ± 20.12 0.654 40.36 ± 23.87 0.569 
 CT 10.45 ± 6.34  32.40 ± 20.64  45.17 ± 30.31  
 TT 10.93 ± 7.62  29.50 ± 17.31  42.70 ± 28.71  
        
rs7720677 CC 10.59 ± 6.52 0.668 30.50 ± 19.15 0.410 43.05 ± 27.54 0.689 
 CT 10.33 ± 5.11  33.12 ± 21.21  44.03 ± 29.08  
 TT 9.39 ± 3.63  25.98 ± 18.99  36.76 ± 28.80  
        
rs6897600 AA 10.43 ± 6.35 0.741 31.20 ± 19.56 0.300 44.05 ± 29.96 0.305 
 AC 10.47 ± 5.82  32.23 ± 20.17  43.73 ± 26.92  
 CC 10.63 ± 5.35  26.97 ± 19.40  35.93 ± 21.59  
 
§ Krustal-Wallis test for siginificance  
 
Abbreviations used: SD – standard deviation 
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4.0 Discussion 
 
Both case-control181-189 and prospective studies144,190-194 have yielded inconsistent results 
regarding the association between prolactin and breast cancer risk. Recently, two large 
prospective studies193,194 reported a significant positive association between prolactin and post-
menopausal breast cancer. The exact mechanism is still unknown, but  it has been hypothesized 
that prolactin and estrogen may act synergistically to exert their mitogenic effects on the normal 
breast180.  Whereas increased levels of estrogen have been linked to increased breast density, 
whether elevated prolactin levels also lead to increases in breast density remains unknown. To 
our knowledge, this is the first study to examine the association between prolactin and breast 
density and variations in the prolactin gene and its’ receptor in a cohort of postmenopausal, 
cancer-free healthy women.   
Women with benign breast masses observed on a routine screening mammogram had a 
greater proportion of breast dense area (50.57 ± 31.57 cm2 vs. 41.38 ± 26.91 cm2), and had 
greater percent breast density (36.44 ± 19.86 vs. 29.87 ± 19.65) when compared with women 
who had negative screening mammograms. This result is not surprising given that higher breast 
density is associated with lower sensitivity and specificity of mammograms, thus resulting in 
false-positive readings (due to lower specificity).   
No statistically significant differences were observed for mean serum prolactin levels 
between both groups of women. This may be the result of the composition of our sample 
population – healthy, cancer-free postmenopausal women.  
A weak, but statistically significant correlation was observed between prolactin and 
percent breast density (spearman correlation coefficient of 0.1197; p-value 0.013) after adjusting 
for ever being pregnant and ever breast feeding, thus confirming our hypothesis that women with 
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elevated prolactin levels will have elevated percent breast density.  Ever being pregnant and ever 
breast feeding were the only two variables for which a positive bi-variate correlation with 
prolactin was observed.  This result is not surprising, given that prolactin acts like both a mitogen 
and differentiating agent during pregnancy and lactation138,177. During pregnancy, breast 
epithelial cells rapidly proliferate to create additional ductal branches and to promote 
lobuloalveolar growth178.  Prolactin acts directly on the mammary epithelium to produce 
lobuloalveolar development171. During lactation, the alveoli serve as the unit of milk production 
and are directly under the control of circulating prolactin180. 
No statistically significant differences were observed for the prolactin gene single 
nucleotide polymorphisms in relation to serum prolactin level, percent breast density, or 
proportion of dense breast area. Prolactin levels, regardless of the SNP tested, fluctuated around 
the mean value of 10.62 ± 6.89  ng/mL, as did percent breast density (31.41 ± 19.87) and 
proportion of dense breast area (43.53 ± 28.30 cm2).   
Two SNPs (rs7734558 and rs7705216) within the prolactin receptor gene failed to reach 
statistical significance at the 0.05 level, they were significant at the 0.10 level (p-value of 0.070 
for rs7734558 and p-value of 0.080 for rs7705216).  Although further analyses are needed, it 
appears that healthy, cancer-free, postmenopausal women with the G allele (AG and GG) had a 
slightly elevated level of prolactin when compared with women homozygous for the A allele 
(AG 10.76 ± 6.40 ng/mL, GG 10.77 ± 4.60 ng/mL vs. AA 9.86 ± 6.32 ng/mL) for SNP 
rs7734558. In regards to SNP rs7705216, healthy, cancer-free, postmenopausal women who 
were homozygous for the GG allele have a slightly elevated prolactin level when compared with 
women with the C allele (GG 11.71 ± 2.78 ng/mL vs. CG 11.15 ± 6.22 ng/mL, CC 10.27 ± 5.99 
ng/mL).   
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Our results are somewhat consistent with a recently published study by Lee et al.211 
which examined the common genetic variation in both the prolactin and prolactin receptor genes 
in relation to plasma prolactin levels and breast cancer risk in the Multiethnic Cohort.  No 
statistically significant associations were observed between any of the tagging SNPs chosen 
(covered 59 kb of the prolactin locus and 210 kb of the prolactin receptor locus) and either 
plasma prolactin levels or breast cancer risk. The authors did not specifically examine the two 
SNPs that were significant at the 0.10 level, thus not allowing for comparison. 
 In contrast to our results, Vaclavicek et al.170 using a case-control study design observed 
that two SNPs (rs1341239 and rs12210179) in the prolactin gene were both statistically 
significantly associated with a higher breast cancer risk (OR 1.67, 95% CI 1.11-2.50, and OR 
2.09, 95% CI 1.23-3.52, respectively). We did not observe any association between these two 
SNPs and elevated levels of breast density in our sample of healthy, cancer-free postmenopausal 
women. One would hypothesize that if both of these SNPs were in fact associated with breast 
cancer risk, that they may also be associated with higher breast density, given the consistently 
observed strong association between breast density and breast cancer risk.  However, this 
discrepancy could be related to the study population.  Whereas Vaclavicek et al.170 utilized a 
case-control study design in which the cases had a very strong family history of breast cancer, 
we utilized a cross-sectional study design of healthy, cancer-free postmenopausal women, of 
which only 14% had a family history of breast cancer in a first-degree relative. In addition, both 
the Lee et al.211 and Vaclavicek et al.170 studies examined the association between prolactin and 
prolactin receptor genes in relation to breast cancer risk, not breast density. 
The main limitation of this study is that the women were all Caucasian and 
postmenopausal, thus limiting the generalizability of the findings to Caucasian post-menopausal 
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women only.  We are not able to draw any conclusions about the association of breast density 
and prolactin in pre-menopausal women or women of other ethnic groups.  
Another limitation is the use of a one-time serum specimen for the evaluation of prolactin 
levels which may not accurately reflect more etiologically-relevant long-term levels. 
Additionally, prolactin has a notable circadian variation, and levels can also be affected by food.  
Specimens were not fasting and were drawn at various times of day, which could impact the 
findings. Because we were unable to adjust for time of day of blood draw and/or month of blood 
draw, it is possible that the results obtained could be an underestimation. 
Additionally, a common concern in candidate-gene association studies is population 
stratification –  the variation in allele frequencies across subgroups of a population that also 
differ in risk factors profiles for the disease.212,213 Population stratification is a form of 
confounding that could introduce false associations.214 However, data suggest that in studies of 
U.S. non-Hispanics of European descent, it is unlikely that the population contains a make-up 
that would lead to appreciably biased estimates of association.  Since most of the Caucasian 
women in this study are of European descent, population stratification should not be a problem.  
We were unable to utilize “genomic control” methods to address this issue.  The basic idea of 
genomic control would be to genotype extra markers that are unlinked to the genes under 
investigation and that are unlikely to be associated with breast density. A standard panel of 
genomic control markers can then be used to estimate any stratification and calculate an 
adjustment parameter. The adjustment is applied to the test statistics in order to make them more 
conservative and account for the estimated level of stratification (if any). This method is well-
supported by both statistical and population-genetic theory, and is in common use for this type of 
study215-218, although it was not conducted by the laboratory used for genotype analyses.  It is 
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also possible that any observed associations found between a SNP and breast density/prolactin 
may be due to linkage disequilibirum between the assessed polymorphism and the true functional 
polymorphism at a nearby locus.   
Despite these limitations, this proposal has several strengths, including the novel 
hypotheses and large sample size (n=445), which will provide ample power to assess the 
association of prolactin with breast density.  In addition, this is the first study of prolactin gene 
variation and breast density in a healthy postmenopausal population.   
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5.0 Conclusion  
 
Although, elevated levels of mammographic breast density are a risk factor for breast cancer 
development, little is correctly known regarding what factors lead to such levels. A factor that 
may contribute to elevated levels of breast density is prolactin.  Prolactin acts like both a mitogen 
and differentiating agent during pregnancy and lactation175,176.  Although the majority of studies 
have yielded inconsistent results regarding the association between prolactin and breast cancer 
risk, the Nurses Health Study194 reported a significant positive association among 
postmenopausal women (RR=1.34, 95% CI 1.02-1.76, highest versus lowest quartile of prolactin 
concentration). However, to date and our knowledge, this is the first study to examine the 
association between prolactin and breast density and variations in the prolactin gene and the 
prolactin receptor gene in a sample of healthy, cancer-free, postmenopausal women.  
A weak, but statistically significant correlation was observed between prolactin and 
percent breast density (spearman correlation coefficient of 0.1197; p-value 0.013) after adjusting 
for ever being pregnant and ever breast feeding, thus confirming our hypothesis that women with 
elevated prolactin levels will have elevated mammographic breast density. 
No statistically significant differences were observed for single nucleotide 
polymorphisms (SNPs) in the prolactin gene.  However, two SNPs in the prolactin receptor gene 
(rs7734558 and rs7705216) were significantly associated with serum prolactin level at the 0.10 
significance level.  Healthy, cancer-free, postmenopausal women with the G allele (AG and GG) 
at SNP rs7734558 have a slightly elevated level of prolactin when compared with women 
homozygous for the A allele (AG 10.76 ± 6.40 ng/mL, GG 10.77 ± 4.60 ng/mL vs. AA 9.86 ± 
6.32 ng/mL). In regards to SNP rs7705216, healthy, cancer-free, postmenopausal women who 
were homozygous for the GG allele have a slightly elevated prolactin level when compared with 
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individuals with the C allele (GG 11.71 ± 2.78 ng/mL vs. CG 11.15 ± 6.22 ng/mL, CC 10.27 ± 
5.99 ng/mL).  Although further analyses are needed, such as examining the potential association 
between the SNPs and serum levels via a dominant, co-dominant, and recessive model, the 
results appear to be promising and warrant further investigation. 
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6.0 Public Health Significance 
 
 
The current study adds to the ever growing body of public health literature on the determinants 
of breast cancer risk, specifically mammographic breast density. As mentioned previously, breast 
density, outside of age and BRCA1/2 mutations, is the strongest risk factor for breast cancer.  
Although it is well known that screening mammography is the best way to reduce morbidity and 
mortality from breast cancer, elevated levels of breast density affect the sensitivity and 
specificity of mammograms, thus reducing the benefits of screening.  It has been proposed that if 
breast density is taken into account in the standard breast cancer risk assessment, that up to 20% 
of postmenopausal women would be eligible for chemoprevention.  It is therefore imperative that 
we understand not only the underlying factors that contribute to breast density, but their 
underlying mechanisms as well, in order to improve breast cancer screening and identify women 
who are at an increased risk for breast cancer and for whom prevention strategies may be useful. 
Although we only observed a weak correlation between prolactin and percent breast 
density (spearman correlation coefficient of 0.1197), it was highly significant (p-value 0.013) 
and confirmed our hypothesis that women with elevated prolactin levels will have an elevated 
percent breast density. Breast cancer is a multi-factorial disease and there is no reason to believe 
that one of it’s most predictive risk factors – percent breast density – would not also be multi-
factorial.  It is very likely that prolactin is only one of several factors that contribute to increased 
breast density.  Further studies are needed to not only confirm our findings, but to further explore 
the relationship between prolactin and other breast cancer predictive factors, such as estrogen 
levels in a cohort of healthy, cancer-free postmenopausal women.   
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Because increased breast density reduces the sensitivity of mammograms, it is essential 
that we understand the determinants of breast density, which may in turn help improve 
mammographic screening. In addition, the current study was limited in that our study population 
only consisted of Caucasian women.  It is possible that prolactin may have a stronger correlation 
with breast density in other population groups, such as African-American women. If a stronger 
correlation/association between prolactin and percent breast density is observed in other 
populations, it could provide the impetus to begin investigating prolactin antagonists as potential 
chemopreventive agents for breast cancer.  
In addition, two SNPs in the prolactin receptor gene (rs7734558 and rs7705216) were 
significantly associated with serum prolactin levels at the 0.10 significance level.  These SNPs 
need to be further investigated not only in our study population, but in other populations as well.  
If polymorphisms in the prolactin gene and/or the prolactin receptor gene are found to be 
statistically associated with increased percent breast cancer, it may be possible to use these 
genetic markers to identify women at an increased risk for breast cancer.  
Our results, along with those of future studies, may lead to improved prevention and early 
detection of breast cancer, thus having an important contribution to public health. 
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